Developments in chemical approaches to treat tuberculosis in the last decade

Current Medicinal Chemistry

Volumn 19, Issue 4, 2012, Pages 488-517

  Tripathi, R P ^a   Bisht, S S ^a   Ajay, A ^a   Sharma, A ^a   Misra, M ^a   Gupt, M P ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Antitubercular agents; Arabinogalactan; Chemotherapy; Extensively drug resistance (XDR); Fatty acid synthase; MultiDrug Resistance (MDR); Mycobacterium tuberculosis; Mycolic acid; Peptidoglycan; Tuberculosis (TB)

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOSALICYLIC ACID; BEDAQUILINE; BENZOTHIAZOLINE DERIVATIVE; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; DELAMANID; DIAMINE DERIVATIVE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PROTIONAMIDE; PYRAZINAMIDE; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; SULFONYLUREA DERIVATIVE; SUTEZOLID; THIOLACTOMYCIN; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; CYTOTOXICITY; DNA REPLICATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EPILEPSY; EXFOLIATIVE DERMATITIS; FOLLOW UP; GASTROINTESTINAL TRACT; HEARING IMPAIRMENT; HELICOBACTER PYLORI; HOMELESSNESS; HUMAN; IC 50; IMMIGRATION; IN VITRO STUDY; IRON METABOLISM; LIVER TOXICITY; MEMBRANE TRANSPORT; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OXIDATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POVERTY; PROTEIN SYNTHESIS INHIBITION; RNA SYNTHESIS; SUICIDE ATTEMPT; TREATMENT DURATION; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; HUMANS; MOLECULAR CONFORMATION; TUBERCULOSIS;

EID: 84863421391     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712798918815     Document Type: Article

References (385)

1. Gradmann, C. Robert Koch and the white death: From tuberculosis to tuberculin. Microbes. Infect., 2006, 8, 294-301. (Pubitemid 43139318)
2. 2010/2011 Tuberculosis Global Facts, http://www.who.int/tb/publications/ global-report/en/index.html (November 2010
3. World Health Organization (2008). "Countries with XDR-TB confirmed cases as of June 2008. www.who.int/tb/challenges/xdr/xdr-map-june08.
4. Dye, C.; Williams, B.G. The Population Dynamics and Control of Tuberculosis. Science, 2010, 328, 856-861.
5. Espinal, M.A.; Kim, S.J.; Suarez, P.G.; Kam, K. M.; Khomenko, A. G.; Migliori, G. B.; Baéz, J.; Kochi, A.; Dye, C.; Raviglione, M.C. Standard Short-Course Chemotherapy for Drug-Resistant Tuberculosis: Treatment Outcomes in Six Countries. JAMA 283(19), 2537-2545 (2000 (Pubitemid 30324196)
6. Russell, D.G.; Barry 3rd, C.E.; Flynn, J.L. Tuberculosis: What We Don't Know Can, and Does, Hurt Us. Science, 2010, 328, 852-856.
7. Rullas, J.; Garcia, J.I.; Beltran, M.; Cardona, P.J.; Cáceres, N.; García-Bustos, J.F.; Angulo-Barturen, I. A fast standardized therapeutic efficacy assay for drug discovery in tuberculosis. Antimicrob. Agents Chemother. doi:10.1128/AAC.01423-09.
8. Nalini, S.L.; Devika, R.K.; Ravikumar, D.; Ramachandran, R. Combined drug medium with isoniazid and rifampicin for identification of multi-drugresistant mycobacterium tuberculosis. Indian J. Med. Microbiol., 2010, 28(2), 162-163.
9. Boehme, C.C.; Nabeta, P.; Hillemann, D.; Nicol, M.P.; Shenai, S.; Krapp, F.; Allen, J.; Tahirli, R.; Blakemore, R.; Rustomjee, R.; Milovic, A.; Jones, M.; O'Brien, S.M.; Persing, D.H.; Ruesch-Gerdes, S.; Gotuzzo, E.; Rodrigues, C.; Alland, D.; Perkins, M.D. Rapid molecular detection of tuberculosis and rifampicin resistance. N. Engl. J. Med., 2010, 363, 1005-1015.
10. Dyrhol-Riise, A.M.; Gran, G.; Wenzel-Larsen, T.; Blomberg, B.; Haanshuus, C.G.; Moerkve, O. Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the Quantiferon-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country. BMC Infectious Diseases, 2010, 10, 1471-2334.
11. Autran, B. Method of Prognosis and/or Diagnosing an Irs in A Patient Infected with M. tuberculosis, and Optionally Hiv, PCT Int. Appl, WO2010089377, December, 2010.
12. Kim, Y.M; Park, S.W.; Song, T. PCT Int. Appl. WO2009-KR7702 (2010
13. Tripathi, R.P.; Tewari, N.; Dwivedi, N.; Tiwari, V.K. Fighting tuberculosis: An old disease with new challenges. Med. Res. Rev., 2005, 25, 93-131. (Pubitemid 39642233)
14. Ballell, L.; Field, R.A.; Duncan, K.; Young, R.J. New Small-Molecule Synthetic Antimycobacterials. Antimicrob. agents and Chemother., 2005, 49, 2153-2163. (Pubitemid 40734441)
15. Janin, Y.L. Antituberculosis drugs: Ten years of research. Bioorg. Med. Chem., 2007, 15, 2479-2513. (Pubitemid 46367698)
16. Kayukova, L.A.; Praliev, K.D. Main directions in the search for new antituberculous drugs (review). Pharm. Chem. J., 2000, 34, 11-18.
17. Newton, S.M.; Lau, C.; Wright, C.W. A review of antimycobacterial natural products. Phytother. Res., 2002, 14, 303-322. (Pubitemid 30655514)
18. Copp, B.R. Antimycobacterial natural products. Nat. Prod. Rep., 2003, 20, 535-557. (Pubitemid 38024760)
19. Okunade, A.L.; Elwin-Lewis, M.P.F.; Lewis, W.H. Natural antimycobacterial metabolites: Current status. Phytochemistry, 2004, 65, 1017-1032. (Pubitemid 38542737)
20. Pinto, S.C.; Leitao, G.G.; Oliveira, D.R.; Bizzo, H.R.; Ramos, D.F.; Coelho, T.S.; Silva, P.E.; Lourenço, M.C.; Leitão, S.G.Chemical Composition and Antimycobacterial Activity of the Essential Oil from Anemia tomentosa var. anthriscifolia. Nat. Prod. Comm., 2009, 4(12), 1675-1678.
21. Negi, A.S.; Kumar, J.K.; Luqman, S.; Saikia, D.; Khanuja, S.P.S. Antitubercular Potential of Plants: A Brief Account of Some Important Molecules. Med. Res. Rev., 2010, 30(4), 603-645.
22. Gupta, R.; Thakur, B.; Singh, P.; Singh, H.B.; Sharma, V.D.; Katoch, V.M.; Chauhan, S.V.S. Anti-tuberculosis activity of selected medicinal plants against multi-drug resistant Mycobacterium tuberculosis isolates. Indian J. Med. Res., 2010, 131, 809-813.
23. Haritakun, R.; Sappan, M.; Suvannakad, R.; Tasanathai, K.; Isaka, M. An Antimycobacterial Cyclodepsipeptide from the Entomopathogenic Fungus Ophiocordycepscommunis BCC 16475. J. Nat. Prod., 2010, 73, 75-78.
24. Chen, J.J.; Lin, W.J.; Shieh, P.C.; Chen, I.S.; Peng, C.F.; Sung, P.J. A New Long-Chain Alkene and Antituberculosis Constituents from the Leaves of Pourthiaea lucida. Eichemistry & biodiversity, 2010, 7, 717-721.
25. Singh, S.; Kumar, J.K.; Shanker, D.S.K.; Thakur, J.P.; Negi, A.S.; Banerjee, S. A bioactive labdane diterpenoid from Curcuma amada and its semisynthetic analogues as antitubercular agents. Eur. J. Med. Chem., 2010, 45, 4379-4382.
26. Scher, J.M.; Schinkovitz, A.; Zapp, J.; Wang, Y.; Franzblau, S.G.; Becker, H.; Lankin, D.C.; Pauli, G.F. Structure and Anti-TB Activity of Trachylobanes from the Liverwort Jungermannia exsertifoliassp. Cordifolia. J. Nat. Prod., 2010, 73, 656-663.
27. Inui, T.; Wang, Y.; Nikolic, D.; Smith, D.C.; Franzblau, S.G.; Pauli, G.F. Sesquiterpenes from Oplopanax horridus. J. Nat. Prod., 2010, 73, 563-567.
28. Pan, P.C.; Cheng, M.J.; Peng, C.F.; Huang, H.Y.; Chen, J.J.; Chen, I.S. Secondary Metabolites from the Roots of Litsea hypophaea and Their Antitubercular Activity. J. Nat. Prod., 2010, 73, 890-896.
29. Kuete, V.; Ngameni, B.; Mbaveng, A.T.; Ngadjui, B.; Marion, M.J.J.; Lall, N. Evaluation of flavonoids from Dorstenia barteri for their antimycobacterial, antigonorrheal and anti-reverse transcriptase activities. Acta Tropica 2010, 116(1), 100-104.
30. Hong, Q.; Minter, D.E.; Franzblau, S.; Arfan, M.; Amin, H.; Reinecke, M.G. Anti-tuberculosis compounds from Mallotus philippinensis. Nat. Prod. Comm., 2010, 5(2), 211-217.
31. Sharma, K.; Chopra, P.; Singh, Y. Recent advances towards identification of new drug targets for Mycobacterium tuberculosis. Expert Opin. Ther. Targets, 2004, 8(2), 79-93. (Pubitemid 38489535)
32. Zhang, Y.; Amzel, L. M. Tuberculosis Drug Targets. Curr. Drug Targets, 2002, 3, 131-154. (Pubitemid 34296204)
33. Duncan, K.; Sacchettini, J.C. Approaches to tuberculosis drug development. Molecular genetics of mycobacteria. In: Hatfull GF, Jacobs WRJ (Ed.), ASM Press, Washington DC, 2000, pp. 297-307.
34. Smith, C.V.; Sacchettini, J.C. Mycobacterium tuberculosis a model system for structural genomics. Curr. Opin. Struct. Biol., 2003, 13, 658-664. (Pubitemid 37522140)
35. Duncan, K. Identification and validation of novel drug targets in tuberculosis. Curr. Pharm. Des.; 2004, 10, 3185-3194. (Pubitemid 39276608)
36. Nayyar, A.; Jain, R. Recent Advances in New Structural Classes of Anti-Tuberculosis Agents. Curr. Med. Chem., 2005, 12, 1873-1886. (Pubitemid 41015184)
37. Mdluli, K.; Spigelman, M. Novel targets for tuberculosis drug discovery. Curr. Opin. Pharmacol., 2006, 6 (5), 459-467. (Pubitemid 44340669)
38. Tomioka, H. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr. Pharm. Des., 2006, 12, 4047-4070. (Pubitemid 44669760)
39. Liu, J.; Ren, H.P. Tuberculosis current treatment and New Drug development Anti-Infective Agents Med. Chem., 2006, 5, 331-344. (Pubitemid 44574832)
40. Maziar, D.; Danielle, D.; Claudio, N.A.; Remold, H.G.; Behar, S.M. Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat. Immunol., 2010, 11(8), 751-758.
41. Behar, S.M.; Divangahi, M.; Remold, H.G. Evasion of innate immunity by Mycobacterium tuberculosis: Is death an exit strategy? Nat. Rev. Microbiol., 2010, 8(9), 668-674.
42. Woodruff, H.B.; Waksman, S.A. The actinomycins and their importance in the treatment of tumors in animals and man. Historical background. Ann. N.Y. Acad. Sci., 1960, 89, 287-298.
43. Lehmann, J. The first clinical trial of streptomycin in human tuberculosis. Dis. Chest, 1949, 16, 684-703.
44. Mark, S.B.; Antony, D.B. Natural products-The future scaffolds for novel antibiotics? Biochem. Pharmacol., 2006, 71, 919-929.
45. Waksman, S.A. Successes and Failures in the search for Antibiotics. Ad. Appl. Microbiol., 1969, 11, 1-16.
46. Domagk, G. Modern methods of chemotherapy of tuberculosis. An. R. Acad. Nac. Med. (Madr.)., 1952, 69, 504-513.
47. Thomas, J.P.; Baughn, C.O.; Wilkinson, R.G.; Shepherd, R.G.A. A new synthetic compound with antituberculous activity in mice: Ethambutol. Am. Re. Respir. Dis., 1961, 83, 891-893.
48. Epstein, I.G.; Nair, K.G.; Boyd, L.J. Cycloserine, a new antibiotic, in the treatment of human pulmonary tuberculosis: A preliminary report. Antibiot. Med. Clin. Ther., 1955, 1, 80-93.
49. Floss, H.G.; Yu, T.W. Rifamycin: Mode of Action, Resistance, and Biosynthesis. Chem. Rev., 2005, 105, 621-632. (Pubitemid 40351636)
50. Boshoff, I.M.; Barry, C.E. III. Tuberculosiss Metabolism and respiration in the absence of growth. Nat. Rev. Microbiol., 2005, 3, 70-80. (Pubitemid 40028470)
51. Godreuil, S.; et al. In Encyclopedia of Infectious Diseases: Modern Methodologies Tibayrenc, M. (Ed.) John Wiley & Sons 2007, pp. 1-30.
52. Johnson, R.; Streicher, E.M.; Louw, G.E.; Warren, R.M.; van Helden, P.D.; Victor, T.C. Drug Resistance in Mycobacterium tuberculosis Curr. Issues. Mol. Biol., 2006, 8, 97-112. (Pubitemid 44121991)
53. American Thoracic Society, Centers for Disease Control and Prevention and Infectious Diseases Society of America. Treatment of tuberculosis. MMWR 52, 1-77 (2003
54. da Silva, P.A.; Ainsa, J.A. In Tuberculosis 2007 From basic science to patient care. 593-633, (2007
55. Nuermberger, E.; Grosset, J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur. J. Clin. Microbiol. Infect. Dis., 2004, 23, 243-255. (Pubitemid 38669936)
56. World Health Organization, Treatment of Tuberculosis Guidelines. http://www.who. int/tb/publications/cds-tb-2003-313/en/index.html & http://www.who.int/tb.xdr/faqs/en/ (2007
57. Smith, C.V.; Sharma, V.; Sacchettini, J.C. TB drug discovery: Addressing issues of persistence and resistance. Tuberculosis (Edinb.), 2004, 84, 45-55. (Pubitemid 38082932)
58. Pilheu, J.A. Tuberculosis 2000: Problems and solutions. Int. J. Tuberculosis Lung Dis., 1998, 2, 696-703. (Pubitemid 28429718)
59. Peloquin, C.A.; Berning, S.E. Infection caused by Mycobacterium tuberculosis. Ann. Pharmacother., 1994, 28, 72-84. (Pubitemid 24042494)
60. Guerrin-Tran, E.; Thiolet, J.M.; Rousseau, C.; Henry, S.; Poirier, C.; Che, D.; Vinas, J.M.; Jarlier, V.; Robert, J. An evaluation of data quality in a network for surveillance of Mycobacterium tuberculosis resistance to antituberculosis drugs in Ile-de-France region-2001-2002. Eur. J. Epidemiol., 2006, 21, 783-785. (Pubitemid 44885199)
61. Murray, J.F. Tuberculosis and HIV Infection: A Global Perspective. Respiration, 1998, 65, 335-342. (Pubitemid 28491266)
62. Gordin, F.M.; Nelson, E.T.; Matts, J.P.; Cohn, D.L.; Ernst, J.; Benator, D.; Besch, C.L.; Crane, L.R.; Sampson, J.H.; Bragg, P.S.; El-Sadr, W. The Impact of HIV Infection on Drug-Resistant Tuberculosis. Am. J. Respir. Crit. Care Med., 1996, 154, 1478-1483. (Pubitemid 26391201)
63. Moss, A.R.; Alland, D.; Telzak, E.; Hewlett, D. Jr.; Sharp, V.; Chiliade, P.; LaBombardi, V.; Kabus, D.; Hanna, B.; Palumbo, L.; Brudney, K.; Weltman, A.; Stoeckle, K.; Chirgwin, K.; Simberkoff, M.; Moghazeh, S.; Eisner, W.; Lutfey, M.; Kreiswirth, B. A city-wide outbreak of a multiple-drug-resistant strain of Mycobacterium tuberculosis in New York. Int. J. Tuberculosis Lung. Dis., 1997, 1, 115-121. (Pubitemid 127509666)
64. National Survey of Tuberculosis in England and Wales. Communicable Dis. Rep. Wkly. 8, 209-212 (1998
65. Cohen, J. Infectious disease: Extensively Drug-Resistant TB Gets Foothold in South Africa. Science, 2006, 313, 1554.
66. Wright, A. Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second Line Drugs Worldwide 2000-2004. MMWR. 2006, 55, 301-305.
67. Stone, R. New Tuberculosis Lab Hailed as Breakthrough in Health Diplomacy. Science, 2010, 327, 1312-1313.
68. Harries, A.D.; Zachariah, R.; Corbett, E.L. The HIV-associated tuberculosis epidemic-when will we act? The Lancet, 2010, 375, 1906-1919.
69. Gandhi, N.R.; Nunn, P.; Dheda, K.; Schaaf, H.S.; Zignol, M.; van Soolingen, D.; Jensen, P.; Bayona, J. Multidrug-resistant and extensively drug-resistanttuberculosis: A threat to global control of tuberculosis. The Lancet, 2010, 1-14.
70. Cole, S.T.; Brosch, R.; Parkhill, J. Nature, 1998, 393, 537-544.
71. Camus, J.C.; Pryor, M.J.; Medigue, C.; Cole, S.T. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology, 2002, 148, 2967-2973. (Pubitemid 35243696)
72. Andries, K.; Verhasselt, P.; Guillemont, J.; Göhlmann, H.W.; Neefs, J.M.; Winkler, H.; Van, G.J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis. Science, 2005, 307, 223-227. (Pubitemid 40116230)
73. Flynn, E.M.; Hanson, J.A.; Alber, T.; Yang, H. Dynamic Active-Site Protection by the M. tuberculosis Protein Tyrosine Phosphatase PtpB Lid Domain. J. Am. Chem. Soc., 2010, 132, 4772-4780.
74. Zhou, B.; He, Y.; Zhanga, X.; Xu, J.; Luo, Y.; Wang, Y.; Franzblau, S.G.; Yang, Z.; Chan, R.J.; Liu, Y.; Zheng, J.; Zhang, Z.Y. Targeting mycobacterium protein tyrosinephosphatase B for antituberculosis agents. Proc Natl Acad Sci U S A., 2010, 107(100), 4573-4578.
75. Vintonyak, V.V.; Warburg, K.; Kruse, H.; Grimme, S.; Hübel, K.; Rauh, D.; Waldmann, H. Identification of Thiazolidinones Spiro-Fused to Indolin-2-ones as Potent and Selective Inhibitors of the Mycobacterium tuberculosis Protein Tyrosine Phosphatase B. Angew. Chem. Int. Ed., 2010, 49, 5902-5905.
76. Mascarello, A.; Chiaradia, L.D.; Vernal, J.; Grimme, S.; Hübel, K.; Rauh, D.; Waldmann, H. Inhibition of Mycobacterium tuberculosis tyrosine phosphatase PtpA by synthetic chalcones: Kinetics, molecular modeling, toxicity and effect on growth. Bioorg. Med. Chem., 2010, 18, 3783-3789.
77. Lu, J.P.; Ye, Q.Z. Expression and characterization of Mycobacterium tuberculosis methionine aminopeptidase type. Bioor. Med. Chem. Lett., 2010, 20, 2776-2779.
78. Olaleye, O.; Raghunand, T.R.; Bhat, S.; He J, Tyagi, S.; Lamichhane, G.; Gu, P.; Zhou, J.; Zhang, Y.; Grosset, J.; Bishai, W.R.; Liu, J.O. Methionine Aminopeptidases from Mycobacterium tuberculosis as Novel Antimycobacterial Targets. Chemistry & Biology, 2010, 17(1), 86-97.
79. Concepcion, G.B.; Filipa, V.P.V.; Sonia, P.G.; Cristina, S.S.; Lorena, T.V.; Competitive inhibitors of type ii dehydroquinase enzyme, Eur. Pat. Appl. EP-2202230, March, 2010.
80. Kumar, A.; Siddiqi, M.I.; Miertus, S. New molecular scaffolds for the design of Mycobacterium tuberculosis type II dehydroquinase inhibitors identified using ligand and receptor based virtual screening. J. Mol. Model., 2010, 16, 693-712.
81. Sledz, P.; Silvestre, H.L.; Hung, A.W.; Ciulli, A.; Blundell, T.L.; Abell, C. Optimization of the Interligand Overhauser Effect for Fragment Linking: Application to Inhibitor Discovery against Mycobacterium tuberculosis Pantothenate Synthetase. J. Am. Chem. Soc., 2010, i 4544-4545.
82. Manos-Turvey, A.; Bulloch, E.M.M.; Rutledge, P.J.; Baker, E.N.; Lott, J.S.; Payne, R.J. Inhibition Studies of Mycobacterium tuberculosis Salicylate Synthase (MbtI). ChemMedChem., 2010, 5, 1067-1079.
83. Talukdar, A.; Morgunova, E.; Duan, J.; Meining, W.; Foloppe, N.; Nilsson, L. Virtual screening, selection and development of a benzindolone structural scaffold for inhibition of lumazine synthase. Bioorg. Med. Chem., 2010, 18, 3518-3534.
84. Phillips, I.; Shannon, K.P. Aminoglycosides and aminocyclitols. Antibiotic and Chemotherapy, 7th Ed. Edinburgh: Churchill Livingstone. 1997, pp. 164-201.
85. Heijenoort, Jv. Formation of the glycan chains in the synthesis of bacterial peptidoglycan. Glycobiology, 2001, 11, 25-36.
86. Dua, R.; Sindhwani, G.; Rawat, J. Exfoliative Dermatitis to All Four First Line Oral Anti-Tubercular Drugs. Indian J. Tuberc.2010, 57, 53-56.
87. Offe, H.A. In: Bartmann, K. (Ed.). Antituberculosis drugs, handbook of experimental pharmocology. Berlin: Springer-Verlag, 1988, Vol. 84, pp. 1-30.
88. Trinka, L.; Mison, P. In: Bartmann K, (Ed.). Antituberculosis drugs, handbook of experimental pharmocology, Berlin: Springer-Verlag. 1988, Vol. 84, pp. 51-68.
89. Rodriguez, G.; Smith, I. Identification of an ABC transporter required for iron acquisition and virulence in Mycobacterium tuberculosis. J. Bacteriol., 2006, 188, 424-430. (Pubitemid 43100529)
90. Nopponpunth, V.; Sirawaraporn, W.; Greene, P.J.; Santi, D.V. Cloning and expression of Mycobacterium tuberculosis and Mycobacterium leprae dihydropteroate synthase in Escherichia coli. J. Bacteriol., 1999, 181, 6814-6821. (Pubitemid 29517998)
91. Meyer, H. Mally, J. "On hydrazine derivatives and pyridine carbonic acids" (in German). Monatshefte Chemie verwandte Teile anderer Wissenschaften, 1912, 23, 393-414.
92. Riede, H.L. Fourth-generation fluoroquinolones in tuberculosis. Lancet, 2009, 373, 1148-1149.
93. Zhang, Y.; Heym, B.; Allen, B.; Young, D.; Cole, S.T. The catalaseperoxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature, 1992, 358, 591-593.
94. Zhang, Y.; Garbe, T.; Young, D. Transformation with katG restores isoniazid-sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol Microbiol., 1993, 8(3), 521-524. (Pubitemid 23156446)
95. Heym, B.; Alzari, P.M.; Honore, N.; Cole, S.T. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol. Microbiol.; 1995, 15(2), 235-245.
96. Mdluli, K.; Slayden, R.A.; Zhu, Y.; Ramaswamy, S.; Pan, X.; Mead, D.; Crane, D.D.; Musser, J.M.; Barry, C.E 3rd. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science, 1998, 280(5369), 1607-1610. (Pubitemid 28277706)
97. Singh, A.K.; Kumar, R.P.; Pandey, N.; Singh, N.; Sinha, M.; Bhushan, A.; Kaur, P.; Sharma, S.; Singh, T.P. Mode of Binding of the Tuberculosis Prodrug Isoniazid to Heme Peroxidases Binding Studies and Crystal Structure of Bovine Lactoperoxidase with Isoniazid At 2.7 A Resolution. The Journal Biological Chemistry, 2010, 285(2), 1569-1576.
98. Wang, F.; Jain, P.; Gulten, G. Liu, Z.; Feng, Y.; Ganesula, K.; Motiwala, A.S.; Ioerger, T.R.; Alland, D.; Vilchèze, C.; Jacobs, W.R.; Jr. Sacchettini, J.C. Mycobacterium tuberculosis Dihydrofolate Reductase Is Not a Target Relevant to the Antitubercular Activity of Isoniazid. Antimicrob. Agents Chemother. 2010, 54(9), 3776-3782.
99. Johnson, K.; Schultz, P.G. Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis. J. Am. Chem. Soc., 1994, 116, 7425-7426. (Pubitemid 24274243)
100. Chopra, I.; Brennan, P.J. Molecular action of anti-mycobacterial agent. Tubercle and Lung, 1998, 78, 89-98.
101. Centers for Disease Control and Prevention. Severe Isoniazid-Associated Liver Injuries Among Persons Being Treated for Latent Tuberculosis Infection -United States, 2004-2008. MMWR, 2010, 59 (8), 224-229.
102. Lu, X.Y.; You, Q.D.; Chen, Y.D. Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis. Mini. Rev. Med. Chem., 2010, 10(3), 182-193.
103. Scorpio, A.; Zhang, Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med., 1996, 2(6), 662-667. (Pubitemid 26191953)
104. McCune, R.M.; Feldman, F.M.; McDermat, W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J. Exp. Med., 1966, 123, 445-468.
105. Centers for Disease Control and Prevention. "Targeted tuberculin testing and treatment of latent tuberculosis infection". MMWR, 2000, 49, 31-32.
106. Konno, K.; Feldmann, F.M.; McDermott, W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am. Rev. Respir. Dis., 1967, 95(3), 461-469.
107. Boshoff, H.I.; Mizrahi, V.; Barry, C.E. III. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J. Bacteriol., 2002, 184, 2167-2172. (Pubitemid 34259666)
108. Zhang, Y.; Wade, M.M.; Scorpio, A.; Zhang, H.; Sun, Z. Mode of action of pyrazinamide: Disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother. 2003, 52, 790-795. (Pubitemid 37407806)
109. McDermott, W.; Tompsett, R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am. Rev. Tuberculosis, 1954, 70(4), 748-754.
110. Shi, W.; Zhang, X.; Jiang, X.; Yuan, H.; Lee, J. S.; Barry 3rd, C. E.; Wang, H.; Zhang, W.; Zhang, Y. Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis. Science, 2011, 333, 1630-1632.
111. Cyanamon, M.H.; Klemmens, S.P. Antimycobacterial activity of a series of pyrazinoic acid esters. J. Med. Chem. 1982, 35, 1212-1215.
112. Otten, H. Experimental evaluation of efficacy VII. Cycloserine (CS) and terizidone (TZ). In Bartman K. (Ed). Antituberculosis drugs. Handbook of experimental Pharmacology, Berlin: Springer Verlog, 1988, Vol. 44, pp. 158-166.
113. Gale, E.F.; Cundliffe, E.; Reynolds, P.E.; Richmond, M.H.; Waring, M.J. The molecular basic of antibitic action, 2nd edition London: John Wiley and Sons, 1981.
114. David, H.L. Takayama K, Goldman DS. Susceptibility of mycobacterial Dalanyl-D-alanine synthetase to D-cycloserine. Am. Rev. Resp. Dis., 1969, 100(4), 579-581.
115. Cacers, N.E.; Harris, N.B.; Wellehen, J.F.; Feng, Z.; Kapur, V.; Barletta, R.G. Overexpression of the D-alanine racemase gene confers resistance to Dcycloserine in Mycobacterium smegmatis J. Bacteriol., 1997, 179, 5046-5055. (Pubitemid 27340537)
116. Baulard, A.R.; Betts, J.C.; Engohang-Ndong, J.; Quan, S.; McAdam, R.A.; Brennan, P.J.; Locht, C.; Besra, G.S. Activation of the Pro-drug Ethionamide Is Regulated in Mycobacteria, J. Biol. Chem. 2000, 275, 28326-28331.
117. DeBarber, A.E.; Mdluli, K.; Bosman, M.; Bekker, L.G.; Barry, C.E., Ethionamide activation and sensitivity in multi-drug resistant Mycobacterium tuberculosis, 3rd. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 9677-9682. (Pubitemid 30650835)
118. Vannelli, T.A.; Dykman, A.; Ortiz de Montellano, P.R. The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase, J. Biol. Chem. 2002, 277, 12824-12829. (Pubitemid 34952646)
119. Qian, L.; Ortiz de Montellano, P.R. Oxidative activation of thiacetazone by the Mycobacterium tuberculosis flavin monooxygenase Eta A and human FMO1 and FMO3, Chem. Res. Toxicol. 2006, 19, 443-449.
120. Morlock, G.P.; Metchock, B.; Sikes, D.; Crawford, J.T.; Cooksey, R.C. ethA, inhA, and katG loci of ethionamide resistant clinical MycoAntimicrob. Agents Chemother. 2003, 47, 3799-3805.
121. Busscher, G.F.; Rutjes, F.P.; van Delft, F.L. 2-Deoxystreptamine: Central scaffold of aminoglycoside antibiotics, Chem. Rev. 2005, 105, 775-791. (Pubitemid 40527375)
122. Carter, A. P.; Clemons, W. M.; Brodersen, D. E.; Morgan-Warren, R. J.; Wimberly, B. T.; Ramakrishnan, V. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics, Nature, 2000, 407, 340-348.
123. Johansen, S. K.; Maus, C. E.; Plikaytis, B. B.; Douthwaite, S. Capreomycin Binds across the Ribosomal Subunit Interface Using tlyA-Encoded 2'-OMethylations in 16S and 23S rRNAs, Mol. Cell, 2006, 23, 173-182. (Pubitemid 44081881)
124. Lambert, P.A.J. Cellular impermeability and uptake of biocides and antibiotics in Gram-positive bacteria and mycobacteria. Appl. Microbiol. 2002, 92, 46S-54S.
125. Senaratne, R.H.; Mobasheri, H.; Papavinasasundaram, K.G.; Jenner, P.; Lea, E.J.; Draper, P. Expression of a Gene for a Porin-Like Protein of the OmpA Family from Mycobacterium tuberculosis H37Rv. J. Bacteriol. 1998, 180, 3541-3547. (Pubitemid 29115081)
126. Niederweis, M. Mycobacterial porins -new channel proteins in unique outer membranes. Mol. Microbiol. 2003, 49, 1167-1177. (Pubitemid 37153488)
127. Mailaender, C.; Reiling, N.; Engelhardt, H.; Bossmann, S.; Ehlers, S.; Niederweis, M. The MspA porin promotes growth and increases antibiotic susceptibility of both Mycobacterium bovis BCG and Mycobacterium tuberculosis, Microbiology, 2004, 150, 853-864. (Pubitemid 38519306)
128. Stephan, J.; Mailaender, C.; Etienne, G.; Daffe, M.; Niederweis, M. Multidrug Resistance of a Porin Deletion Mutant of Mycobacterium smegmatis, Antimicrob. Agents Chemother. 2004, 48, 4163-4170. (Pubitemid 39434870)
129. Yendapally, R.; Lee, R.E. Synthesis and Evaluation of Novel Ethambutol Analogues. Bioorg. Med. Chem. Lett., 2008, 18(5), 1607-1611. (Pubitemid 351318253)
130. Rastogi, N.; Labrousse, V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampicin against Mycobacterium avium complex. Antimicrob. Agents Chemother., 1991, 35(3), 462-470.
131. Inderlied, C.B.; Barbara-Burnham, L.; Wu, M.; Young, L.S.; Bermudez, L.E.M. Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages. Antimicrob. Agents Chemother., 1994, 38, 1838-1843. (Pubitemid 24250734)
132. Mikusova, K.; Slayeden, R.A.; Besra, G.S.; Brennan, P.J. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob. Agents Chemother., 1995, 39, 2484-2489.
133. Tumbanatham, A.; Vinodkumar, S. Ofloxacin induced arthropathy in patients with multi-drug resistance tuberculosis. J. Assoc. of Physicians India, 2000, 48(6), 647-648.
134. Renau, T.E.; Gage, J.W.; Dever, J.A.; Roland, G.E.; Joannides, E.T.; Shapiro, M.A.; Sanchez, J.P.; Gracheck, S.J.; Domagala, J.M.; Jacobs, M.R.; Reynolds, R.C. Structure activity relationships of quinolone agents against mycobacteria: Effect of structural modifications at the 8 position. Antimicrob. Agents Chemother., 1996, 40, 2363-2368. (Pubitemid 26328047)
135. Elsea, S.H.; Osheroff, N.; Nitiss, J.L. Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast. J. Biol. Chem., 1992, 267(19), 13150-13153.
136. Wolfson, J.S.; Hooper, D.C. The fluoroquinolones: Structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob. Agents Chemother., 1985, 28, 581-586. (Pubitemid 16236555)
137. Levine, C.; Hiasa, H.; Marians, K.J. DNA gyrase and topoisomerase IV: Biochemical activities physiological roles during chromosome replication and drug sentivities. Biochem. Biophys. Acta., 1998, 1400, 29-43. (Pubitemid 28475094)
138. Albrecht, R. Development of antibacterial agents of the nalidixic acid type. Prog. Drug Res., 1977, 21, 9-104.
139. Jaber, L.A.; Bailey, E.M.; Rybak, M.J. Enoxacin: A new fluoroquinolone. Clin. Pharm.; 1989, 8, 97-107. (Pubitemid 19087240)
140. Wise, R.; Andrews, J.M.; Edwards, L.J. In vitro Activity of Bay 09867, a New Quinoline Derivative, Compared with Those of Other Antimicrobial Agents. Antimicrob. Agents Chemother., 1983, 23, 559-564. (Pubitemid 13163297)
141. Sato, K.; Matsuura, Y.; Inoue, M.; Une, T.; Osada, Y.; Ogawa, H.; Mitsuhashi, S. In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob. Agents Chemother., 1982, 22, 548-553. (Pubitemid 13206530)
142. Atarashi, S.; Yokahama, S.; Yamazaki, K.; Sakano, K.; Imamura, M.; Hayakawa, I. Chem. Pharm. Bull., 1987, 35, 1896.
143. Blondeau, J.M. Gatifloxacin: A new fluoroquinolone. Expert Opin. Invest. Drugs, 2000, 9, 1877-1895. (Pubitemid 30639336)
144. Nightingale, C.H. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: A review of microbiologic and pharmacokinetic-dynamic characteristics. Pharmacotherapy, 2000, 20, 245.
145. Gellert, M.; Mizuuchi K, O'Dea, M.H.; Nash, H.A. DNA gyrase: An enzyme that introduces superhelical turns into DNA. Proc. Natl. Acad. Sci. U.S.A., 1976, 73, 3872-3876.
146. Kato, J.; Nishimura, Y.; Imamura, R.; Niki, H.; Hiraga, S.; Suzuki, H. New topoisomerase essential for chromosome segregation in E. coli. Cell, 1990, 63, 393-404.
147. Takei, M.; Fukuda, H.; Kishii, R.; Hosaka, M. Target Preference of 15 Quinolones against Staphylococcus aureus, Based on Antibacterial Activities and Target Inhibition. Antimicrob. Agents Chemother. 2001, 45, 3544-3547. (Pubitemid 33107875)
148. Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S.V.; Eiglmeier, K.; Gas, S.; Barry, C.E 3rd, Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.; Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M.A.; Rajandream, M.A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J.E.; Taylor, K.; Whitehead, S.; Barrell, B.G. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 1998, 393, 537-544. (Pubitemid 28319235)
149. Molina-Torres, C.A.; Ocampo-Candiani, J.; Rendon, A.; Pucci, M.J.; Vera-Cabrera, L. In Vitro Activity of a New Isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and Other Mycobacteria. Antimicrob. Agents Chemother., 2010, 54(5), 2188-2190.
150. Saraiva, M.F.; de Souza, M.V.N.; Tran Huu Dau, M.E.; Araujo, D.P.; de Carvalho, G.S.G.; de Almeida, M.V. Synthesis and antitubercular evaluation of new fluoroquinolone derivatives coupled with carbohydrates. Carbohydr. Res. 2010, 345(6), 761-767.
151. Webster, D.; Long, R.; Shandro, C.; Pettipas, J.; Leblanc, J.; Davidson, R.; Fanning, A. Fluoroquinolone resistance in renal isolates of Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis., 2010, 14(2) 217-222.
152. Parneti, F.; Lancini, G. Rifamycins In: O'Grady F, Lambert HP, Finch RG, Greenwood, D. eds. Antibitic and Chemotherapy, 7theds. Edinburg: Churchill Livingston, 1997, pp. 453-459.
153. Masters, S.B.; Trevor, A.J.; Katzung, B.G. Katzung & Trevor's pharmacology. New York: Lange Medical Books/McGraw Hill, Medical Pub (2005
154. Robin, P.M.; Reznik, T.; Kutlin, A.; Hammerschlag, M.R. In vitro Activities of Rifamycin Derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and Recent Clinical Isolates of Chlamydia pneumonia. Antimicrob. Agents Chemother., 2003, 47, 1135-1136. (Pubitemid 36254248)
155. Velichka, D.; Ivana, A.; Haruaki, T.; Katsumasa, S.; Venkata, R.; Nadadhur, G.; Donna, D.; Todor, K.; Arvind, D.; Yurii, F.; Ljudmila, Y.; Toumanov, A.; Zvetana, Z.; Chiaki, S. Experimental and clinical studies on Rifacinna: The new effective antituberculous drug (review). Recent Pat. on AntiInfect. Drug Discov., 2010, 5(1), 76-90.
156. Park, Y.K.; Kim, B.J.; Ryu, S.; Kook, Y.H.; Choe, Y.K.; Bai, G.H.; Kim, S.J. Cross-resistance between rifampicin and KRM-1648 is associated with rpoB alleles in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis., 2002, 6(2), 166-170. (Pubitemid 34263710)
157. Stover, C.K.; Warrener, P.; VanDevanter, D.R.; Sherman, D.R.; Arain, T.M.; Langhorne, M.H.; Anderson, S.W.; Towell, J.A.; Yuan, Y.; McMurray, D.N.; Kreiswirth, B.N.; Barry, C.E.; Baker, W.R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, 405, 962-966 and references cited therein. (Pubitemid 30435054)
158. Lenaerts, A.J.; Gruppo, V.; Marietta, K.S.; Johnson, C.M.; Driscoll, D.K.; Tompkins, N.M.; Rose, J.D.; Reynolds, R.C. Orme IM.Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother., 2005, 49, 2294-2301. (Pubitemid 40734457)
159. Tyagi, S.; Nuermberger, E.; Yoshimatsu, T.; Williams, K.; Rosenthal, I.; Lounis, N.; Bishai, W.; Grosset, J. Bactericidal Activity of the Nitroimidazopyran PA-824 in a Murine Model of Tuberculosis. Antimicrob. Agents Chemother., 2005, 49, 2289-2293. (Pubitemid 40734456)
160. Sasaki, H.; Hasegawa, T.; .Sumida, T.; Matsumoto, M.; Tsubouchi, H.; Haraguchi, Y.; Kuroda, T.; Tai, K.; Matsuzaki, T.; Miyamura, S.; Kuroda, H.; Itotani, M.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Komatsu, M.; Seike, Y. 2,3-dihydro-6-nitroimidazo 2,1-b oxazoles, EP-1555267-A1, July, 2005.
161. Tsubouchi, H.; Sasaki, H.; Itotani, M.; Haraguchi, Y.; Miyamura, S.; Matsumoto, M.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Ohguro, K.; Sumida, T.; Hasegawa, T.; Tanaka, K.; Takemura, I. 2, 3-Hihydro-6-nitroimidazo (2, 1-b) oxazole compounds for the treatment of tuberculosis, WO05042542A1, 2005.
162. Rivers, E.C.; Mancera, R.L. New Anti-Tuberculosis Drugs with Novel Mechanisms of Action. Curr. Med. Chem. 2008, 15, 1956-1967.
163. Sasaki, H.; Haraguchi, Y.; Itotani, M.; Kuroda, H.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Matsumoto, M.; Komatsu, M.; Tsubouchi, H. Synthesis and Antituberculosis Activity of a Novel Series of Optically Active 6-Nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J. Med. Chem.; 2006, 49, 7854-7860. (Pubitemid 46033674)
164. Contreras, G.; Sung, J.C.; Muttil, P.; Padilla, D.; Telko, M.; Verberkmoes, J.L.; Elbert, K.J.; Hickey, A.J.; Edwards, D.A. Dry Powder PA-824 Aerosols for Treatment of Tuberculosis in Guinea Pigs. Lucila. Antimicrob. Agents Chemother., 2010, 54, 1436-1442.
165. Maroz, A.; Shinde, S.S.; Franzblau, S.G.; Ma, Z.; Denny, W.A.; Palmer, B.D. Anderson RF. Release of nitrite from the antitubercular nitroimidazole drug PA-824 and analogues upon one-electron reduction in protic, nonaqueous solvent. Org. Biomol. Chem., 2010, 8, 413-418.
166. Singh, R. Manjunatha, U. Boshoff, H.I. Ha, Y.H.; Niyomrattanakit, P.; Ledwidge, R.; Dowd, C.S.; Lee, I.Y.; Kim, P.; Zhang, L.; Kang, S.; Keller, T.H.; Jiricek, J.; Barry, C.E. 3rd. PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release. Science, 2008, 322, 1392-1395. (Pubitemid 352775253)
167. Lounis, N.; Veziris, N.; Chauffour, A.; Truffot-Pernot, C.; Andries, K.; Jarlier, V. Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment Duration. Antimicrob. Agents Chemother., 2006, 50, 3543-3547. (Pubitemid 44684863)
168. Reddy, V.M.; Einck, L.; Andries, K.; Nacy, C.A. In Vitro Interactions between New Antitubercular Drug Candidates SQ109 and TMC207. Antimicrob. Agents Chemother., 2010, 54, 2840-2846.
169. Guillemont JEG, van Gestel JFE, Venet MG, Poignet HJJ, Decrane LFB, Vernier DFJ. Patent WO200411436 (2004
170. Huitric, E.; Verhasselt, P.; Koul, A.; Andries, K.; Hoffner, S.; Andersson, D.I. Rates and Mechanisms of Resistance Development in Mycobacterium tuberculosis to a Novel Diarylquinoline ATP Synthase Inhibitor. Antimicrob. Agents Chemother., 2010, 54(3), 1022-1028.
171. Deidda, D.; Lampis, G.; Fioravanti, R.; Biava, M.; Porretta, G.C.; Zanetti, S.; Pompei, R. Bactericidal Activities of the Pyrrole Derivative BM212 against Multidrug-Resistant and Intramacrophagic Mycobacterium tuberculosis Strains. Antimicrob. Agents Chemother., 1998, 42, 3035-3037. (Pubitemid 28501251)
172. Arora SK, Sinha N, Jain A, et al. Patent WO200426828 (2004
173. Arora, S.K.; Sinha, N.; Sinha, R.; Upadhayaya, R.S. Antimycobacterial Pharmaceutical Composition, Patent US20050256128, November, 2005.
174. Chen, P.; Gearhart, J.; Protopopova, M.; Einck, L.; Nacy, C.A. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J. Antimicro. Chemotherapy. 2006, 58, 332-337. (Pubitemid 44294944)
175. Protopopova, M.; Hanrahan, C.; Nikonenko, B.; Samala, R.; Chen, P.; Gearhart, J.; Einck, L.; Nacy, C.A. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J. Antimicrob. Chemother., 2005, 56, 968-974. (Pubitemid 41631930)
176. Jia, L.; Tomaszewski, J.E.; Hanrahan, C.; Coward, L.; Noker, P.; Gorman, G.; Nikonenko, B.; Protopopova, M. Pharmacodynamics and pharmacokinetics of SQ109, a new diamin-based antitubercular drug. Br. J. Pharmacol., 2005, 144, 80-87. (Pubitemid 40192564)
177. Onajole, O.K.; Govender, P.; Van Helden, P.D.; Kruger, H.G.; Maguire, G.E.; Wiid, I.; Govender, T. Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates. Eur. J. Med. Chem. 2010, 45(5), 2075-2079.
178. Das, B.; Rudra, S.; Yadav, A.; Ray, A.; Rao, A.V.; Srinivas, A.S.; Soni, A.; Saini, S.; Shukla, S.; Pandya, M.; Bhateja, P.; Malhotra, S.; Mathur, T.; Arora, S.K.; Rattan, A.; Mehta, A. Synthesis and SAR of novel oxazolidinones: Discovery of ranbezolid. Bioorg. Med. Chem. Lett., 2005, 15, 4261-4267. (Pubitemid 41187998)
179. Alcala, L.; Ruiz-Serrano, M.J.; Turegano, C.P.F.; de Viedma, D.G.; Diaz-Infantes, M.; Marin-Arriaza, M.; Bouza, E. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob. Agents Chemother., 2003, 47, 416-417. (Pubitemid 36070399)
180. Williams, K.N.; Stover, C.K.; Zhu, T.; Tasneen, R.; Tyagi, S.; Grosset, J.H.; Nuermberger, E. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother., 2009, 53, 1314-1319.
181. Omura, S.; Nakagawa, A.; Iwata, R.; Takahashi, Y.; Shimizu, H.; Tanaka, H. Thiotetromycin, a new antibiotic. Taxonomy, production, isolation, and physicochemical and biological properties. J. Antibiot.(Tokyo), 1983, 36, 109-114. (Pubitemid 13148116)
182. Noto, T.; Miyakawa, S.; Oishi, H.; Endo, H.; Okazaki, H. Thiolactomycin, a new antibiotic. III. In vitro antibacterial activity. J Antibiot (Tokyo), 1982, 35(4), 401-410. (Pubitemid 12046394)
183. Omura, S.; Nakagawa, A.; Iwata, R.; Hatano, A. Structure of a new antibacterial antibiotic, thiotetromycin. J. Antibiot., 1983, 36, 1781-1782. (Pubitemid 14182445)
184. Nishida, I.; Kawaguchi, A.; Yamada, M. Effect of thiolactomycin on the individual enzymes of the fatty acid synthase system in Escherichia coli. J. Biochem., 1986, 99, 1447-1454. (Pubitemid 16033515)
185. Slayden, R.A.; Lee, R.E.; Armour, J.W.; Cooper, A.M.; Orme, I.M.; Brennan, P.J.; Besra, G.S. Antimycobacterial action of thiolactomycin: An inhibitor of fatty acid and mycolic acid synthesis. Antimicrob. Agents Chemother., 1996, 40, 2813-2819. (Pubitemid 26404350)
186. Lu, X.; Chen, Y.; You, Q. 3D-QSAR, molecular docking studies, and binding mode prediction of thiolactomycin analogs as mtFabH inhibitors. J. Enzyme Inhib. Med. Chem., 2010, 25(2), 240-249.
187. Shizuri, Y.; Niwa, M.; Furukawa, H.; Yamamura, S. Isolation and structure of citroethiolactone, a novel metabolite of Penicillium citreo-viridebe. Tetrahedron Lett., 1983, 24, 1053-1054. (Pubitemid 13124097)
188. Dolak, L.A.; Castle, T.M.; Truesdell, S.E.; Sebek, O.K. Isolation and structure of antibiotic U-68,204, a new thiolactone. J. Antibiot., 1986, 39, 26-31. (Pubitemid 16174633)
189. Kremer, L.; Douglas, J.D.; Baulard, A.R.; Cooper, A.M.; Orme, I.M.; Brennan, P.J.; Besra, G.S. Thiolactomycin and Related Analogues as Novel Anti-mycobacterial Agents Targeting KasA and KasB Condensing Enzymes in Mycobacterium tuberculosis. J. Biol. Chem., 2000, 275, 16857-16864. (Pubitemid 30398921)
190. Senior, S.J.; Illarionov, P.A.; Gurcha, S.S.; Campbell, I.B.; Schaeffer, M.L.; Minnikin, D.E.; Besra, G.S. Biphenyl-based analogues of thiolactomycin, active against Mycobacterium tuberculosis mtFabH fatty acid condensing enzyme. Bioorg. Med. Chem. Lett., 2003, 13, 3685-3688. (Pubitemid 37206487)
191. Tangallapally, R.P.; Yendapally, R.; Lee, R.E.; Hevener, K.; Jones, V.C.; Lenaerts, A.J.; McNeil, M.R.; Wang, Y.; Franzblau, S.; Lee, R.E. Synthesis and Evaluation of Nitrofuranylamides as Novel Antituberculosis Agents. J. Med. Chem., 2004, 47, 5276-5283. (Pubitemid 39314926)
192. Tangallapally, R.P.; Yendapally, R.; Lee, R.E.; Lenaerts, A.J. Synthesis and Evaluation of cyclic secondary amine substituted phenyl and benzyl nitrofuranyl amides as novel antituberculosis agents. J. Med. Chem., 2005, 48, 8261-8269. (Pubitemid 43032535)
193. Tangallapally, R.P.; Lee, R.E.; Lenaerts, A.J. Synthesis of new and potent analogues of antituberculosis agent 5-nitro-furan-2carboxylic acid 4-(4-benzyl-piperazin-1-yl)-benzylamide with improved bioavailability. Bioorg. Med. Chem. Lett., 2006, 16, 2584-2589.
194. Tawari, N.R.; Degani, M.S. Pharmacophore Mapping and Electronic Feature Analysis for a Series of Nitroaromatic Compounds with Antitubercular Activity. J. Comput. Chem., 2010, 31, 739-751.
195. Sriram, D.; Yogeeswari, P.; Vyas, D.R.K.; Senthilkumar, P.; Bhat, P.; Srividya, M. 5-Nitro-2-furoic acid hydrazones: Design, synthesis and in vitro antimycobacterial evaluation against log and starved phase cultures. Bioorg. Med. Chem. Lett., 2010, 20, 4313-4316.
196. McKinney, J.D.; Honer zu Bentrup, K.; Muñoz-Elías, E.J.; Miczak, A.; Chen, B.; Chan, W.T.; Swenson, D.; Sacchettini, J.C.; Jacobs, W.R Jr, Russell, D.G. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature, 2000, 406, 735-738.
197. Biava, M.; Porretta, G.C.; Poce, G.; De Logu, A.; Saddi, M.; Meleddu, R.; Manetti, F.; De Rossi, E.; Botta, M. 1,5-Diphenylpyrrole derivatives as antimycobacterial agents. Probing the influence on antimycobacterial activity of lipophilic substituents at the phenyl rings. J. Med. Chem., 2008, 51, 3644-3648. (Pubitemid 351875020)
198. Biava, M.; Porretta, G.C.; Poce, G.; De Logu, A.; Meleddu, R.; De Rossi, E.; Manetti, F.; Botta, M. 1,5-Diaryl-2ethyl pyrrole derivatives as antimycobacterial agents: Design, synthesis and microbiological evaluation. European J. Med. Chem., 2009, 44, 4734-4738.
199. Joshi, S.D.; Vagdevi, H.M.; Vaidya, V.P.; Gadaginamath, G.S. Synthesis of new 4-pyrrol-1yl benzoic acid hydrazide analogs and derived oxadiazole, triazole and pyrrole ring systems: A novel class of potential antibacterial and antitubercular agents. Eur. J. Med. Chem., 2008, 43, 1989-1996.
200. Hearn, M.J.; Chen, M.F.; Terrot, M.S.; Webster, E.R.; Cynamon, M.H. Preparation and properties in vitro and in vivo of antitubercular pyrroles. J. Het. Chem., 2010, 47(3), 707-712.
201. Sharma, R.N.; Sharma, K.P.; Dixit, S.N. Synthesis, Charecterization, and Biological Activities of some New Pyrazoline Derivatives, derived from Ethyl-2-(2, 5-dichloroanilido) Acetohydrazide, Int. J. ChemTech Research, 2010, 2 (3), 1413-1425.
202. Sivakumar, P.M.; Seenivasan, S.P.; Kumar, V.; Doble, M. Novel 1,3,5-triphenyl-2-pyrazolines as anti-infective agents Bioorg. Med. Chem. Lett., 2010, 20, 3169-3172.
203. Joshi, S.D.; Joshi, A.; Vagdevi, H.M.; Vaidya, V.P.; Gadaginamath, G.S. Synthesis of some new quinolinylpyrazoles as potential antibacterial and antitubercular agents. Ind. J. Het. Chem., 2010, 19(3), 221-224.
204. Lee, R.E.; Protopopova, M.; Crooks, E.; Slayden, R.A.; Terrot, M.; Barry, C.E III. Combinatorial Lead Optimization of [1, 2]-Diamines Based on Ethambutol as Potential Antituberculosis Preclinical Candidates. J. Comb. Chem., 2003, 5(2), 172-187. (Pubitemid 37123511)
205. Ralambomanana, D.A.; Ramilison, D.R.; Rakotohova, A.C.; Maugein, J.; Pelinski, L. Synthesis and antitubercular activity of ferrocenyl diaminoalcohols and diamines. Bioorg. Med. Chem, 2008, 16, 9546-9553.
206. Zhang, X.; Hu, Y.; Chen, S.; Luo, R.; Yue, J.; Zhang, Y.; Duan, W.; Wang, H. Synthesis and evaluation of (S,S)-N,N'-bis-[3-(2,2',6,6'- tetramethylbenzhydryloxy)-2-hydroxy-propyl]-ethylenediamine (S2824) analogs with anti-tuberculosis activity. Bioorg. Med. Chem. Lett., 2009, 19, 6074-6077.
207. Nefzi, A.; Appel, J.; Arutyunyan, S.; Houghten, R.A. Parallel synthesis of chiral pentamines and pyrrolidine containing bis-heterocyclic libraries. Multiple scaffolds with multiple building blocks: A double diversity for the identification for the identification of new antitubercular compounds. Bioorg. Med. Chem. Lett., 2009, 19, 5169-5175.
208. Onajole, O.; Govender, K.K.; Govender, P.; van Helden PD, Kruger, H.G.; Maguire, G.E.; Muthusamy, K.; Pillay, M.; Wiid, I.; Govender, T. Pentacyclo-undecane derived cyclic tetra-amines: Synthesis and evaluation as potent antituberculosis agents. Eur J Med. Chem., 2009, 44, 4297-4305.
209. Tripathi, R.P.; Tripathi, R.; Tiwari, V.K.; Bala, L.; Sinha, S.; Srivastava, A.; Srivastava, R.; Srivastava, B.S. Synthesis of glycosylated β-amino acids as new class of antitubercular agents. Eur. J. Med. Chem., 2002, 37, 773-781. (Pubitemid 35279245)
210. Sohn, H.; Lee, K.S.; Ko, Y.K.; Ryu, J.W.; Woo, J.C.; Koo, D.W.; Shin, S.J.; Ahn, S.J.; Shin, A.R.; Song, C.H.; Jo, E.K.; Park, J.K.; Kim, H.J. In vitro and ex vivo activity of new derivatives of acetohydroxyacid synthase inhibitors against Mycobacterium tuberculosis and non-tuberculous mycobacteria. Int J. Antimicro. Agents, 2008, 31, 567-571.
211. Gundersen, L.L.; Nissen-Meyer, J.; Spilsberg, B. Synthesis and antimycobacterial activity of 6-arylpurines: The requirements for the N-9 substituent in active antimycobacterial purines. J. Med. Chem., 2002, 45, 1383-1386. (Pubitemid 34263575)
212. Ortega, M.A.; Montoya, M.E.; Jaso, A.; Zarranz, B.; Tirapu, I.; Aldana, I.; Monge, A. Antimycobacterial activity of new quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives. Pharmazie, 2001, 56, 205-207. (Pubitemid 32209943)
213. Carta, A.; Paglietti, G.; Rahbar Nikookar, M.E.; Sanna, P.; Sechi, L.; Zanetti, S. Original article Novel substituted quinoxaline 1,4-dioxides with in vitro antimycobacterial and anticandida activity. Eur. J. Med. Chem., 2002, 37, 355-366. (Pubitemid 34465545)
214. Ancizu, S.; Moreno, E.; Solano, B.; Villar, R.; Burguete, A.; Torres, E.; Pérez-Silanes, S.; Aldana, I.; Monge, A. New 3-methylquinoxaline-2- carboxamide 1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents Bioorg. Med. Chem.; 2010, 18, 2713-2719.
215. Ramalingam, P.; Ganapaty, S.; Rao, Ch.; Babu, R. In vitro antitubercular and antimicrobial activities of 1-substituted 2,3(1H,4H)-quinoxalinediones. Bioorg. Med. Chem. Lett., 2010, 20(1), 406-408.
216. Savini, L.; Chiasserini, L.; Gaeta, A.; Pellerano, C. Synthesis and antitubercular evaluation of 4-quinolylhydrazines. Bioorg. Med. Chem., 2002, 10, 2193-2198.
217. de Souza, M.V.N.; Pais, K.C.; Kaiser, C.R.; Peralta, M.A.; Ferreira, M. deL.; Lourenço, M.C.S. Synthesis and in vitro antitubercular activity of a series of qunoline derivatives. Bioorg. Med. Chem.; 2009, 17, 1474-1480.
218. Upadhayaya, R.S.; Kulkarni, G.M.; Vasireddy, N.R.; Vandavasi, J.K.; Dixit, S.S.; Sharma, V.; Chattopadhyaya, J. Design synthesis and biological evaluation of novel triazole, urea and thiourea derivatives of quinoline against Mycobaterium tuberculosis. Bioorg. Med. Chem., 2009, 17, 4681-4692.
219. Gemmaa S, Savini L, Altarelli M, Tripaldi, P.; Chiasserini, L.; Coccone, S.S.; Kumar, V.; Camodeca, C.; Campiani, G.; Novellino, E.; Clarizio, S.; Delogu, G.; Butini, S. Development of antitubercular compounds based on a 4-quinolylhydrazone scaffold. Further structure-activity relationship studies. Bioorg. Med. Chem, 2009, 17, 6063-6072.
220. Eswaran, S.; Adhikari, A.V.; Pal, N.K.; Chowdhury, I.H. Design and synthesis of some new quinoline-3-carbohydrazone derivatives as potential antimycobacterial agents. Bioorg. Med. Chem. Lett., 2010, 20, 1040-1044.
221. Balamurugan, K.; Jeyachandran, V.S.; Perumal, T.H.; Manjashetty, P.; Yogeeswari, D.S. A microwave-assisted, facile, regioselective Friedlander synthesis and antitubercular evaluation of 2,9-diaryl-2,3-dihydrothieno-[3,2-b] quinolines. Eur. J. Med. Chem., 2010, 45, 682-688.
222. Upadhayaya, R.S.; Vandavasi, J.K.; Kardile, R.A.; Lahore, S.V.; Dixit, S.S.; Deokar, H.S.; Shinde, P.D.; Sarmah, M.P.; Chattopadhyaya, J. Novel quinoline and naphthalene derivatives as potent antimycobacterial agents. Eur. J. Med. Chem., 2010, 45, 1854-1867.
223. Upadhayaya, R.S.; Lahore, S.V.; Sayyed, A.Y.; Dixit, S.S.; Shind, P.D.; Chattopadhyaya, J. Conformationally-constrained indeno[2,1-c]quinolines a new class of anti-mycobacterial agents. Org. Biomol. Chem., 2010, 8, 2180-2197.
224. Eswaran, S.; Adhikari, A.V.; Chowdhury, I.H.; Pal, N.K.; Thomas, K.D. New quinoline derivatives: Synthesis and investigation of antibacterial and antituberculosis properties. Eur. J. Med. Chem., 2010, 45, 3374-3383.
225. Eswaran, S.; Adhikari, A.V.; Kumar, A.R. New 1,3-oxazolo[4,5-c]quinoline derivatives: Synthesis and evaluation of antibacterial and antituberculosis properties. Eur. J. Med. Chem., 2010, 45(3), 957-966.
226. Jialin, M.; Hai, Y.; Yuehong, W. Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs. Bioorg. Med. Chem. Lett., 2010, 20(3), 1263-1268.
227. Eswaran, S.; Adhikari, A.V.; Pal, N.K.; Chowdhury, I.H. Design and synthesis of some new quinoline-3-carbohydrazone derivatives as potential antimycobacterial agents. Bioorg. Med. Chem. Lett., 2010, 20(3), 1040-1044.
228. Balamurugan, K.; Jeyachandran, V.; Perumal, S.; Manjashetty, T.H.; Yogeeswari, P.; Sriram, D. A microwave-assisted, facile, regioselective Friedlaender synthesis and antitubercular evaluation of 2,9-diaryl-2,3- dihydrothieno-[3,2-b]quinolines. Eur. J. Med. Chem, 2010, 45(2), 682-688.
229. Yang, C.L.; Tseng, C.H.; Chen, Y.L.; Lu, C.M.; Kao, C.L.; Wu, M.H.; Tzeng, C.C. Identification of benzofuro[2,3-b]quinoline derivatives as a new class of antituberculosis agents. Eur. J. Med. Chem., 2010, 45(2), 602-607.
230. Bonde, C.G.; Gaikwad, N.J. Synthesis and preliminary evaluation of some pyrazine containing thiazoline and thiazolidinones as antimicrobial agents. Bioorg. Med. Chem., 2004, 12, 2151-2161. (Pubitemid 38476974)
231. Huang, Q.; Mao, J.; Wan, B.; Brun, R.; Franzblau, S.G.; Kozikowski, A.P. Searching for New Cures for Tuberculosis: Design, Synthesis, and Biological Evaluation of 2-Methylbenzothiazoles. J. Med. Chem., 2009, 52, 6757-6767.
232. Turan-Zitouni, G.; Kaplancikli, Z.A.; Oezdemir, A. Synthesis and antituberculosis activity of some N-pyridyl-N'-thiazolylhydrazine derivatives. Eur. J. Med. Chem., 2010, 45(5), 2085-2088.
233. Suresh, K.G.V.; Rajendraprasad, Y.; Mallikarjuna, B.P.; Chandrashekar, S.M.; Kistayya, C. Synthesis of some novel 2-substituted-5-[isopropylthiazole] clubbed 1,2,4-triazole and 1,3,4-oxadiazoles as potential antimicrobial and antitubercular agents. Eur. J. Med. Chem., 2010, 45(5), 2063-2074.
234. Guzeldemirci, N.U.; Kucukbasmaci, O. Synthesis and antimicrobial activity evaluation of new 1,2,4-triazoles and 1,3,4-thiadiazoles bearing imidazo[2,1-b]thiazole moiety. Eur. J. Med. Chem., 2010, 45(1), 63-68.
235. Guo, S.; Song, Y.; Huang, Q.; Wang, Y.; Brun, R.; Franzblau, S.G.; Kozikowski, A.P. Identification, synthesis and pharmacological evaluation of tetrahydroindazole based ligands as novel antituberculosis agents. J. Med. Chem., 2010, 53, 649-659.
236. Tripathi, R.P.; Yadav, A.K.; Ajay, A.; Bisht, S.S.; Chaturvedi, V.; Sinha, S.K. Application of Huisgen (3+2) cycloaddition reaction: Synthesis of 1-(2,3-dihydrobenzofuran-2-yl-methyl [1,2,3]-triazoles and their antitubercular evaluations. Eur. J. Med. Chem., 2010, 45(1), 142-148.
237. Gobis, K.; Foks, H.; Zwolska, Z.; Augustynowicz-Kopec, E. Synthesis and tuberculostatic activity of novel 1,2,4-triazoles obtained from heterocyclic carbohydrazides. Heterocycles, 2010, 81(4), 917-934.
238. Singh, B.K.; Yadav, A.K.; Kumar, B.; Gaikwad, A.; Sinha, S.K.; Chaturvedi, V.; Tripathi, R.P. Preparation and reactions of sugar azides with alkynes: Synthesis of sugar triazoles as antitubercular agents. Carbohydr. Res., 2008, 343, 1153-1162.
239. Kucukguzel, I.; Kucukguzel, S.G.; Rollas, S.; Kiraz, M. Some 3-Thioxo/alkylthio-1,2,4-triazoles with a substituted thiourea moiety as possible antimycobacterials. Bioorg. Med. Chem. Lett., 2001, 11, 1703-1707. (Pubitemid 32568302)
240. Costa, M.S.; Boechat, N.; Rangel, E.A da Sil.; va Fde, C.; de Souza, A.M.; Rodrigues, C.R.; Castro, H.C.; Junior, I.N.; Lourenço, M.C.; Wardell, S.M.; Ferreira, V.F. Synthesis, tuberculosis inhibitory activity, and SAR study of N-substituted-phenyl-1,2,3-triazole derivatives. Bioorg. Med. Chem., 2006, 14, 8644-8653. (Pubitemid 44679826)
241. Kumar, G.V.S.; Rajendraprasad, Y.; Mallikarjuna, B.P.; Chandrashekar, S.M.; Kistayya, C. Synthesis of some novel 2-substituted-5-[isopropylthiazole] clubbed 1,2,4-triazole and 1,3,4-oxadiazoles as potential antimicrobial and antitubercular agents. Eur. J. Med. Chem., 2010, 45, 2063-2074.
242. Pochet, S.; Dugue, L.; Douguet, D.; Labesse, G.; Munier-Lehmann, H. Nucleoside Analogues as Inhibitors of Thymidylate Kinases: Possible Therapeutic Applications. ChemBioChem, 2002, 3, 108-110. (Pubitemid 34464803)
243. Vanheusden, V.; Munier-Lehmann, H.; Pochet, S.; Herdewijn, P.; Van Calenbergh, S. Synthesis and evaluation of thymidine-5'-O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase. Bioorg. Med. Chem. Lett., 2002, 12, 2695-2698. (Pubitemid 35247620)
244. Munier-Lehmann, H.; Pochet, S.; Dugue, L.; Dutruel, O.; Labesse, G.; Douget, D. Design of Mycobacterium tuberculosis thymidine monophosphate kinase inhibitors. Nucleosides Nucleotides Nucleic Acids, 2003, 22, 801-804. (Pubitemid 37139261)
245. Haouz, A.; Vanheusden, V.; Munier-Lehmann, H.; Froeyen, M.; Herdewijn, P.; Van Calenbergh, S.; Delarue, M. Enzymatic and structural analysis of inhibitors designed against Mycobacterium tuberculosis thymidylate kinase. New insights into the phosphoryl transfer mechanism. J. Biol. Chem., 2003, 278, 4963-4971. (Pubitemid 36801005)
246. Vanheusden, V.; Van Rompaey, P, Munier-Lehmann, H.; Pochet, S.; Herdewijn, P.; Van Calenbergh, S. Thymidine and thymidine-5'-Omonophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase. Bioorg. Med. Chem. Lett., 2003, 13, 3045-3048. (Pubitemid 36993633)
247. Vanheusden, V.; Munier-Lehmann, H.; Froeyen, M.; Busson, R.; Rozenski, J.; Herdewijn, P.; Van Calenbergh, S. Discovery of Bicyclic Thymidine analogues as selective and high-affinity inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase. J. Med. Chem., 2004, 47, 6187-6194. (Pubitemid 39587243)
248. Van Daele, I.; Munier-Lehmann, H.; Hendrickx, P.M.; Marchal, G.; Chavarot, P.; Froeyen, M.; Qing, L.; Martins, J.C.; Van Calenbergh, S. Synthesis and Biological Evaluation of Bicyclic Nucleosides as Inhibitors of M. tuberculosis Thymidylate Kinase. ChemMedChem, 2006, 1, 1081-1090. (Pubitemid 44622249)
249. Barrow, E.W.; Westbrook, L.; Bansal, N.; Suling, W.J.; Maddry, J.A.; Parker, W.B.; Barrow, W.W. Antimycobacterial activity of 2-methyladenosine. Antimicrob. Agents Chemother., 2003, 52, 801-808.
250. Czaplinski, K.H.; Hansel, W.; Wiese, M.; Seydel, J.K. New benzylpyrimidines: Inhibition of DHFR from various species. QSAR, CoMFA and PC analysis. Eur. J. Med. Chem., 1995, 30, 779-787.
251. Ducati, R.G.; Basso, L.A.; Santos, D.S.; de Azevedo, Jr. W.F. Crystallographic and docking studies of purine nucleoside phosphorylase from Mycobacterium tuberculosis. Bioorg. Med. Chem., 2010, 18, 4769-4774.
252. Czaplinski, K.H.; Hansel, W.; Wiese, M.; Seydel, J.K. New benzylpyrimidines: Inhibition of DHFR from various species. QSAR, CoMFA and PC analysis. Eur. J. Med. Chem.; 1995, 30, 779-787.
253. Dosso, M.; Ouattara, L.; Cherif, A.M.; Bouzid, S.A.; Haller, L.; Fernex, M. Experimental in vitro Efficacy Study on the Interaction of Epiroprim plus Isoniazid against Mycobacterium tuberculosis. Chemotherapy, 2001, 47, 123-127. (Pubitemid 32149703)
254. Brodin, P.; Christophe, T.; No, Z.; Kim, J.; Genovesio, A.; Fenistein, D.P.; Jeon, H.; Ewann, F. A.; Kang, S.; Lee, S.; Seo, M. J.; Park, E.; Contreras Dominguez, M.; Nam, J.Y.; Kim, E.H. Pyridopyrimidine Compounds as Anti-Tubercular Agents, PCT Int. Appl., WO2010003533, 2010.
255. Erkin, A.V.; Krutikov, V.I. Effect of Halogen Atom Localization on the Level of Antimycobacterial Activity of 2-Amino-4-arylamino-6-methylpyrimidines. Russian Journal of General Chemistry. 2010, 80(4), 818-824.
256. Read, M.L.; Braendvang, M.; Miranda, P.O.; Gundersen, L.L. Synthesis and biological evaluation of pyrimidine analogs of antimycobacterial purines. Bioorg. Med. Chem., 2010, 18, 3885-3897.
257. Bacelar, A.H.; Carvalho, M.A.; Proenca, M.F. Synthesis and in vitro evaluation of substituted pyrimido[5,4-d]pyrimidines as a novel class of Antimycobacterium tuberculosis agents Eur. J. Med. Chem., 2010, 45 , 3234-3239.
258. Geist, J.G.; Lauw, S.; Illarionova, V.; Fischer, M.; Gräwert, T.; Rohdich, F.; Eisenreich, W.; Kaiser, J.; Groll, M.; Scheurer, C.; Wittlin, S.; AlonsoGómez, J.L.; Schweizer, W.B.; Bacher, A.; Diederich, F. Thiazolopyrimidine Inhibitors of 2-Methylerythritol 2,4-Cyclodiphosphate Synthase (IspF) from Mycobacterium tuberculosis and Plasmodium falciparum. ChemMedChem, 2010, 5(7), 1092-1101.
259. Suling, W.J.; Maddry, J.A. Antimycobacterial activity of 1-deaza-7,8-dihydropteridine derivatives against Mycobacterium tuberculosis and Mycobacterium avium complex in vitro. J. Antimicrob. Chemother., 2001, 47, 451-454. (Pubitemid 32303412)
260. Sunduru, N.; Gupta, L.; Chaturvedi, V.; Dwivedi, R.; Sinha, S.; Chauhan, P.M.S. Discovery of new 1,3,5-triazine scaffolds withpotent activity against Mycobacterium tuberculosis H37Rv. Eur. J. Med. Chem., 2010, 45, 3335-3345.
261. Bergmann, K.E.; Cynamon, M.H.; Welch, J.T. Quantitative Structure-Activity Relationships for the in Vitro Antimycobacterial Activity of Pyrazinoic Acid Esters. J. Med. Chem., 1996, 39, 3394-3400. (Pubitemid 26322865)
262. Wachter, G.A.; Davis, M.C. Martin AR, Franzblan SG. Antimycobacterial Activity of Substituted Isosteres of Pyridine-and Pyrazinecarboxylic Acids. J. Med. Chem. 1998, 41, 2436-2438. (Pubitemid 28285745)
263. Gezginci, M.H.; Martin, A.R.; Franzblau, S.G. Antimycobacterial activity of substituted isosteres of pyridine and pyrazinecarboxylic acids. 2. J. Med. Chem., 2001, 44(10), 1560-1563. (Pubitemid 32852198)
264. Govindarajan, R.; Bhat, A.R. Synthesis of pyrazinyl and related heterocycles as possible antitubercular agents. Indian J. Heterocyclic Chemistry. 2002, 11(4), 337-338. (Pubitemid 40768213)
265. Sharma, G.K.; Pathak, D. 3D-QSAR study on ring substituted imidazoles for their antitubercular activity. Lett. Drug Design Discovery, 2010, 7(2), 128-132.
266. Sivendran, S.; Jones, V.; Sun, D.; Wang, Y.; Grzegorzewicz, A.E.; Scherman, M.S.; Napper, A.D.; McCammon, J.A.; Lee, R.E.; Diamond, S.L.; McNeil, M. Identification of triazinoindol-benzimidazolones as nanomolar inhibitors of the Mycobacterium tuberculosis enzyme TDP-6-deoxy-D-xylo-4-hexopyranosid-4-ulose 3,5-epimerase (RmlC). Bioorg. Med. Chem., 2010, 18(2), 896-908.
267. Pandey, J.; Tiwari, V.K.; Verma, .S.S.; Chaturvedi, V.; Bhatnagar, S.; Sinha, S.; Gaikwad, A.N.; Tripathi, R.P. Synthesis and antitubercular screening of imidazole derivatives. Eur. J. Med. Chem., 2009, 44, 3350-3355.
268. Kumar, R.R.; Perumal, S.; Senthilkumar, P.; Yogeeswari, P.; Sriram, D. Discovery of antimycobacterial spiro-piperidin-4ones: An atom economic, stereoselective synthesis, and biological intervention. J. Med. Chem., 2008, 51, 5731-5735 (2008
269. Karthikeyan, S.V.; Bala, B.D.; Raja, V.P.A.; Perumal, S.; Yogeeswari, P.; Sriram, D. A highly atom economic, chemo-region-and stereoselective synthesis and evaluation of spiro-pyrrolothiazoles as antitubercular agents. Bioorg. Med. Chem. Lett., 2010, 20, 350-353.
270. Das, U.; Das, S.; Bandy, B.; Stables, J.P.; Dimmocka, J.R. N-Aroyl-3,5-bis(bezylidene)-4-piperidones: A novel class of antimycobacterial agents. Bioorg. Med. Chem., 2008, 16, 3602-3607. (Pubitemid 351484043)
271. Aridoss, G.; Amirthaganesan, S.; Kumar, N.A.; Kim, J.T.; Lim, K.T.; Kabilan, S.; Jeong, Y.T. A facile synthesis, antibacterial, and antitubercular studies of some piperin-4-one and tetrahydropyridine derivatives. Bioorg. Med. Chem. Lett., 2008, 18, 6542-6548.
272. Kumar, R.S.; Perumal, S.; Shetty, K.A.; Yogeeswari, P.; Sriram, D. 1,3-Dipolar cycloaddition of C-aryl-N-phenylnitrones to (R)-1-(1-phenylethyl)-3- [(E)-arylmethylidene]tetrahydro-4(1H)-pyridinones: Synthesis and antimycobacterial evaluation of enantiomerically pure spiroisoxazolidines. Eur. J. Med. Chem., 2010, 45(1), 124-133.
273. Lefevre, P.; Peirs, P.; Braibant, M.; Fauville-Dufaux, M.; Vanhoof, R.; Huygen, K.; Wang, X.M.; Pogell, B.; Wang, Y.; Fischer, P.; Metz, P.; Content, J. Antimycobacterial activity of synthetic pamamycins. J. Antimicrob. Chemother., 2004, 54, 824-827. (Pubitemid 39386739)
274. Pasca, M.R.; Degiacomi, G.; Ribeiro, A.L.; Zara, F.; De Mori, P.; Heym, B.; Mirrione, M.; Brerra, R.; Pagani, L.; Pucillo, L.; Troupioti, P.; Makarov, V.; Cole, S.T.; Riccardi G.Clinical Isolates of Mycobacterium tuberculosis in Four European Hospitals Are Uniformly Susceptible to Benzothiazinones. Antimicrob. Agents Chemother. 2010, 54(4), 1616-1618.
275. Riccardi G, Mannina G, Pasca MR, et al. PCT Int. Appl. WO2010048976 (2010
276. Moraski, G.C.; Franzblau, S.G.; Miller, M.J. Utilization of the Suzuki coupling to enhance the antituberculosis activity of aryloxazoles. Heterocycles, 2010, 80(2), 977-988.
277. Tangallapally, R.P.; Sun, D.; Rakesh, B.N.; Budha, N.; Lee, R.E.; Lenaerts, A.J.; Meibohm, B.; Lee, R.E. Discovery of novel isoxazolines as antituberculosis agents. Bioorg. Med. Chem. Lett., 2007, 17, 6638-6642. (Pubitemid 350026312)
278. Barbachyn, M.R.; Cleek, G.J.; Dolak, L.A.; Garmon, S.A.; Morris, J.; Seest, E.P.; Thomas, R.C.; Toops, D.S.; Watt, W.; Wishka, D.G.; Ford, C.W.; Zurenko, G.E.; Hamel, J.C.; Schaadt, R.D.; Stapert, D.; Yagi, B.H.; Adams, W.J.; Friis, J.M.; Slatter, J.G.; Sams, J.P.; Oien, N.L.; Zaya, M.J.; Wienkers, L.C.; Wynalda, M.A.Identification of phenylisoxazoline as novel antibacterial agents gram-positive pathogens. J. Med. Chem., 2003, 46, 284.
279. Moraski, G.C.; Chang, M.; Villegas-Estrada, A.; Franzblau, S.G.; Moellmann, U.; Miller, M.J. Structure-activity relationship of new antituberculosis agents derived from oxazoline and oxazole benzyl esters. Eur. J. Med. Chem., 2010, 45(5), 1703-1716.
280. Bairwa, R.; Kakwani, M.; Tawari, N.R.; Lalchandani, J.; Ray, M.K.; Rajan, M.G.; Degani, M.S. Novel molecular hybrids of cinnamic acids and guanylhydrazones as potential antitubercular agents. Bioorg. Med. Chem. Lett., 2010, 20, 1623-1625.
281. Aponte, J.C.; Vaisberg, A.J.; Castillo, D.; Gonzalez, G.; Estevez, Y.; Arevalo, J.; Quiliano, M.; Zimic, M.; Verástegui, M.; Málaga, E.; Gilman, R.H.; Bustamante, J.M.; Tarleton, R.L.; Wang, Y.; Franzblau, S.G.; Pauli, G.F.; Sauvain, M.; Hammond, G.B.Trypanoside, anti-tuberculosis, leishmanicidal, and cytotoxic activities of tetrahydrobenzothienopyrimidines. Bioorg. Med. Chem., 2010, 18, 2880-2886.
282. Singh, S.; Mandal, P.K.; Singh, N.; Misra, A.K.; Singh, S.; Chaturvedi, V.; Sinha, S.; Saxena, A.K. Substituted hydrazinecarbothioamide as potent antitubercular agents: Synthesis and quantitative structure-activity relationship (QSAR) Bioorg. Med. Chem. Lett., 2010, 20, 2597-2600.
283. Kocyigit, K.B.; Rollas, S. Synthesis, characterization and evaluation of antituberculosis activity of some hydrazones. Farmaco., 2010, 57(7), 595-599.
284. Savini, L.; Chiasserini, L.; Gaeta, A.; Pellerano, C. Synthesis and antitubercular evaluation of 4-quinolylhydrazones. Bioorg. Med. Chem., 2010, 10, 2193-2198.
285. Karali, N.; Kocabalkanli, A.; Gursoy, A.; Ates, O. Synthesis and antitubercular activity of 4-(3-coumarinyl)-3-cyclohexyl-4-thiazolin-2-one benzylidenehydrazones. Farmaco., 2002, 57, 589-593. (Pubitemid 34765753)
286. Cocco, M.T.; Congiu, C.; Onnis, V.; Pusceddu, M.C.; Schivo, M.L.; Logu, A.D. Synthesis and antimycobacterial activity of some isonicotinoylhydrazones. Eur. J. Med. Chem., 1999, 34, 1071-1076. (Pubitemid 30035911)
287. Ramamurthy, B.; Bhatt, M.V. Synthesis and antitubercular activity of N-(2-naphthyl)glycine hydrazide analogs. J. Med. Chem., 1989, 32, 2421-2426. (Pubitemid 19269969)
288. Nalavde, Y.M.; Josho, V. Synthesis of new fluorine substituted hydrazinecarboxamides and hydrazine carbothioamides having antitubercular and fungicidal activity. Ind. J. Chem., 2000, 39B, 634-637.
289. Miniyar, P.B.; Bhat, A.R. Pyrazinoic acid hydrazide derivatives: Synthesis and antimycobacterial activities. Ind J Het Chem., 1999, 9, 155-156.
290. Sriram, D.; Yogeeswari, P.; Senthilkumar, P.; Sangaraju, D. 5-Nitrothiazolylthiosemicarbazones: Synthesis and antimycobacterial evaluation against tubercular and non-tubercular mycobacterial species. J. Enzyme Inhib. Med. Chem., 2010, 25(1), 105-110.
291. Jolly, V.S.; Sharma, K.P. Studies on aryl thiosemicarbazones and 2-oxo-2-thiazolin-2-ylhydrazones. J. Ind. Chem. Soc., 1990, 67(5), 412-413.
292. Para, A.; Klisiewicz-Panszczyk, T.; Jurek, I. Synthesis and in vitro tuberculostatic activity of Co (II), Cu (II) and Ni (II) complexes of dialdehyde starch dithiosemicarbazone. Acta Pol Pharm., 2001, 58, 405-408. (Pubitemid 33076823)
293. Collins, F.M.; Klayman, D.L.; Morrison, N.E. Correlations between Structure and Antimycobacterial Activity in a Series of 2-Acetylpyridine Thiosemicarbazones. J. Gen. Microbiol., 1982, 128, 1349-1356. (Pubitemid 12037168)
294. Logua, A.D.; Saddi, M.; Onnis, V.; Sanna, C.; Congiu, C.; Borgna, R.; Cocco, M.T. In vitro antimycobacterial activity of newly synthesised Salkylisothiosemicarbazone derivatives and synergistic interactions in combination with rifamycins against Mycobacterium avium. Int. J. Antimicrob. Agents, 2005, 26, 28-32. (Pubitemid 40854112)
295. Cocco, M.T.; Congiu, C.; Onnis, V.; Pellerano, M.L.; Logu, A.D. Synthesis and antimycobacterial activity of new S-alkylisothiosemicarbazone derivatives. Bioorg. Med. Chem., 2002, 10, 501-506. (Pubitemid 34112441)
296. Deshmukh, N.J.; Kulkarni, R.A.; Deodhar, K.D. Reactions of cyclic anhydrides with thiosemicarbazides: Synthesis and antituberculosis activity of glutaconylthiosemicarbazide and its cyclic analogs. Ind. J. Chem., 1985, 24B(3), 330-332.
297. Adams, L.B.; Sinha, I.; Franzblau, G.S.; Krahenbuhl, J.L.; Mehta, R.T. Effective treatment of acute and chronic murine tuberculosis with liposomeencapsulated clofazimine. Antimicrob. Agents Chemother., 1999, 43,
298. Field, S.K.; Cowie, R.L. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest, 2003, 124, 1482-1786.
299. Reddy, V.M.; Srinivasan, S.; Gangadharam, P.R. In vitro and in vivo synergistic effect of isoniazid with streptomycin and clofazimine against Mycobacterium avium complex (MAC). Tuber. Lung Dis., 1994, 75, 208-212. (Pubitemid 24217279)
300. Reddy, V.M.; Nadadhur, G.; Daneluzzi, D.; O'Sullivan, J.F.; Gangadharam, P.R. Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Antimicrob. Agents Chemother., 1996, 40, 633-636. (Pubitemid 26075433)
301. Reddy, V.M.; O'Sullivan, J.F.; Gangadharam, P.R.J. Antimycobacterial activities of riminophenazines. J. Antimicrob. Chemother., 1999, 43, 615-623. (Pubitemid 29231686)
302. Viveiros, M.; Amaral, L. Enhancement of antibiotic activity against polydrug-resistant Mycobacterium tuberculosis by phenothiazines. Int J. Antimicro. Agents, 2001, 17, 225-228. (Pubitemid 32229901)
303. Amaral, L.; Kristiansen, J.E.; Abebe, L.S.; Millett, W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: Potential use for initial therapy of freshly diagnosed tuberculosis. J. Antimicrob. Chemother., 1996, 38, 1049-1053. (Pubitemid 27073284)
304. Amaral, L.; Kristiansen, J.E.; Viveiros, M.; Atougui, J. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: A review supporting further studies that may elucidate the potential use of thioridazine as an anti-tuberculosis therapy. J. Antimicrob. Chemother., 2001, 47, 505-511. (Pubitemid 32447635)
305. Amarala, L.; Boereeb, M.J.; Gillespie, S.H.; Udwadiad, Z.F.; Soolingene, D.V. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J. Antimicro. Agents, 2010, 35, 524-526.
306. Temple, C.G.; Wheeler, G.P.; Elliott, R.D.; Rose, J.D.; Comber, R.N.; Montgomery, J.A. 1,2-Dihydropyrido[3,4-O]pyrazines: Structure-activity relationships. J. Med. Chem., 1983, 26, 91-95.
307. Hunt, E. Pleuromutilin antibiotics. Drugs Future, 2000, 25, 1163-1168. (Pubitemid 32094765)
308. Long, K.S.; Hansen, L.H.; Jakobsen, L.; Vester, B. Interaction of Pleuromutilin Derivatives with the Ribosomal Peptidyl Transferase Center. Antimicrob. Agents Chemother., 2006, 50, 1458-1462.
309. Schluenzen, F.; Pyetan, E.; Fucini, P.; Yonath, A.; Harms, J.M. Inhibition of peptide bond formation by pleuromutilins: The structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol. Microbiol., 2004, 54, 1287-1294. (Pubitemid 39578271)
310. Jones, P.B.; Parrish, N.M.; Houston, T.A.; Stapon, A.; Bansal, N.P.; Dick, J.D.; Townsend, C.A. New Class of Anti-Tuberculosis Agents J. Med. Chem., 2000, 43, 3304-3314.
311. D'Oca, C.D.R.M.; Coelho, T.; Marinho, T.G.; Duarte, C.R.L.H.R.; da Silva, P.A.; D'Oca, M.G.M. Synthesis and antituberculosis activity of new fatty acid amides. Bioorg. Med. Chem. Lett., 2010, 20, 5255-5257.
312. Bakkestuen, A.K.; Gundersen, L.L.; Utenova, B.T. Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines. J. Med. Chem., 2005, 48, 2710-2723.
313. Braendvang, M.; Gundersen, L.L. Selective anti-tubercular purines: Synthesis and chemotherapeutic properties of 6-aryl-and 6-heteroaryl-9- benzylpurines. Bioorg. Med. Chem., 2005, 13, 6360-6373. (Pubitemid 41539300)
314. Pathak, A.K.; Pathak, V.; Seitz, L.E.; Suling, W.J.; Reynolds, R.C. Antimycobacterial agents. 1. Thio Analogues of Purines. J. Med. Chem., 2004, 47, 273-276. (Pubitemid 38040510)
315. Carta, A.; Loriga, M.; Paglietti, G.; Mattana, A.; Fiori, P.L.; Mollicotti, P.; Sechi, L.; Zanetti, S. Synthesis, anti-mycobacterial, anti-trichomonas and anti-candida in vitro activities of 2-substituted-6,7- difluoro-3-methylquinoxaline 1,4-dioxides. Eur. J. Med. Chem.; 2004, 39, 195-203. (Pubitemid 38249532)
316. Muramatsu, Y.; Ishii, M.M.; Inukai, M. Studies on novel bacterial translocase I inhibitors, A-500359s. II. Biological activities of A-500359 A, C, D and G. J. Antibiot., 2003, 56, 253-258. (Pubitemid 36443393)
317. Muramatsu, Y.; Miyakoshi, S.; Ogawa, Y.; Ohnuki, T.; Ishii, M.M.; Arai, M.; Takatsu, T.; Inukai, M. Studies on novel bacterial translocase I inhibitors, A-500359s. III. Deaminocaprolactam derivatives of capuramycin: A-500359 E, F, H; M-1 and M-2. J. Antibiot., 2003, 56, 259-267. (Pubitemid 36443394)
318. Muramatsu, Y.; Ohnuki, T.; Ishii, M.M.; Kizuka, M.; Enokita, R.; Miyakoshi, S.; Takatsu, T.; Inukai, M. A-503083 A, B, E and F, Novel Inhibitors of Bacterial Translocase I, Produced by Streptomyces sp. SANK 62799. J. Antibiot., 2004, 57, 639-646. (Pubitemid 39472814)
319. Koga, T.; Fukuoka, T.; Doi, N.; Harasaki, T.; Inoue, H.; Hotoda, H.; Kakuta, M.; Muramatsu, Y.; Yamamura, N.; Hoshi, M.; Hirota, T. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo. J. Antimicrob. Chemother., 2004, 54, 755-760. (Pubitemid 39386727)
320. Dwivedi, N.; Tewari, N.; Tiwari, V.K.; Chaturvedi, V.; Manju, Y.K.; Srivastava, A.; Giakwad, A.; Sinha, S.; Tripathi, R.P. An efficient synthesis of aryloxyphenyl cyclopropyl methanones: A new class of anti-mycobacterial agents. Bioorg. Med. Chem. Lett., 2005, 15, 4526-4530. (Pubitemid 41253887)
321. Fassihi, A.; Azadpour, Z.; Delbari, N.; Saghaie, L.; Memarian, H.R.; Sabet, R.; Alborzi, A.; Miri, R.; Pourabbas, B.; Mardaneh, J.; Mousavi, P.; Moeinifard, B.; Sadeghi-Aliabadi, H. Synthesis and antitubercular activity of novel 4-substituted imidazolyl-2,6-dimehtyl-N3,N5-bisaryl-1,4-dihydropyridine-3, 5-dicarboxamides. Eur. J. Med. Chem., 2009, 44, 3253-3258.
322. Rossini, M.; Budriesi, R.; Bixel, M.G.; Bolognesi, M.L.; Chiarini, A.; Hucho, F.; Krogsgaard-Larsen, P.; Mellor, I.R.; Minarini, A.; Tumiatti, V.; Usherwood, P.N.; Melchiorre, C. Design, synthesis, and biological evaluation of symmetrically and unsymmetrically substituted methoctramine related polyamines as muscular nicotinic receptor noncompetitive antagonists. J. Med. Chem., 1999, 42, 5212-5223. (Pubitemid 30020272)
323. Manvar, A.T.; Pissurlenkar, R.R.S.; Virsodia, V.R.; Upadhyay, K.D.; Manvar, D.R.; Mishra, A.K.; Acharya, H.D.; Parecha, A.R.; Dholakia, C.D.; Shah, A.K.; Coutinho, E.C. Synthesis, in vitro antitubercular activity and 3DQSAR study of 1,4-dihydropyridines, Mol. Divers., 2010, 14, 285-305.
324. Gupta, S.; Singla, R.; Behera, D.; Khayyam, K.; Korde, R.; Malhotra, P.; Natarajan, K.; Srivastava, V. Pharmaceutical Compositions Containing Calcium Channel Blockers for Treatment of Tuberculosis, PCT Int. Appl. WO2010026602, March, 2010.
325. Alvey, L.; Prado, S.; Huteau, V.; Saint-Joanis, B.; Michel, S.; Koch, M.; Cole, S.T.; Tillequin, F.; Janin, Y.L. A new synthetic access to furo[3,2-f]chromene analogues of an antimycobacterial. Bioorg. Med. Chem., 2008, 16, 8264-8272.
326. Alvey, L.; Prado, S.; Saint-Joanis, B.; Michel, S.; Koch, M.; Cole, S.T.; Tillequin, F.; Janin, Y.L. Diversity-oriented synthesis of furo[3,2-f]chromanes with antimycobacterial activity. Eur. J. Med. Chem., 2009, 44, 2497-2505.
327. Katiyar, D.; Tiwari, V.K.; Tripathi, R.P.; Srivastava, A.; Chaturvedi, V.; Srivastava, R.; Srivastava, B.S. Synthesis and antimycobacterial activity of 3,5-disubstituted thiadiazine thiones. Bioorg. Med. Chem., 2003, 11, 4369-4375. (Pubitemid 37103108)
328. Kelly, M.T.; Andersen, R.J.; Barsby, T.A. Antifungal And Antimycobacterial Basiliskamides, Patent CA 2273436, December, 2000.
329. Tewari, N.; Tiwari, V.K.; Mishra, R.C.; Tripathi, R.P.; Srivastava, A.K.; Ahmad, R.; Srivastava, R.; Srivastava, B.S. Synthesis and bioevaluation of glycosyl ureas as α-glucosidase inhibitors and their effect on mycobacterium. Bioorg. Med. Chem., 2003, 11, 2911-2922. (Pubitemid 36683010)
330. Tripathi, R.P.; Verma, S.S.; Pandey, J.; Agarwal, K.C.; Chaturvedi, V.; Manju, Y.K.; Srivastva, A.K.; Gaikwad, A.; Sinha, S. Search of antitubercular activities in tetrahydroacridines: Synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2006, 16, 5144-5147. (Pubitemid 44247693)
331. Singh, N.; Pandey, J.; Yadav, A. A facile synthesis of α,α'-(EE)-bis(benzylidene)-cycloalkanones and their antitubercular evaluations. Eur. J. Med. Chem., 2009, 44, 1705-1709.
332. Tripathi, R.P.; Saxena, N.; Tiwari, V.K.; Verma, S.S.; Chaturvedi, V.; Manju, Y.K.; Srivastva, A.K.; Gaikwad, A.; Sinha,qa S. Synthesis and antitubercular activity of substituted phenylmethyl-and pyridylmethyl amines. Bioorg. Med. Chem., 2006, 14, 8186-8196. (Pubitemid 44667562)
333. Kittakoop, P.; Nopichai, S.; Thongon, N.; Charoenchai, P.; Thebtaranonth, Y.; Bauhinoxepins, A. B. New antimycobacterial dibenzo[b,f]oxepins from Bauhinia saccocalyx. Helvetica chimica acta, 2004, 87, 175-179. (Pubitemid 38250123)
334. Zampieri, D.; Mamolo, M.G.; Laurini, E.; Scialino, G.; Banfi, E. Vio L. 2-aryl-3-(1H-azol-1-yl)-1H-indole derivatives: A new class of antimycobacterial compounds conventional heating in comparison with MWassisted synthesis. Arch. Pharm. Chem. Life Sci., 2009, 342, 716-722.
335. Johnson, R.E.; Soria, A.E.; O'Connor, J.R.; Dobson, R.A. Synthesis and antibacterial activity of 1-(arylamino)-1H-pyrroles and 4-(1H-pyrrol-1-ylimino)- 2,5-cyclohexadienes. J. Med. Chem., 1981, 24, 1314-1319. (Pubitemid 12209062)
336. Manian, A.K.; Khadse, B.G.; Sengupta, S.R. Synthesis of methyl/ethyl 4-substituted-benzoylthiazole-2-carbamates as potential chemotherapeutic agents. Ind. J. Chem.; 1993, 32B, 407-409.
337. Desai, N.C. Synthesis and antimicrobial activity of some dithiocarbamates, 2-arylimino-4-oxothiazolidines and their 5-arylidene derivatives. Ind. J. Chem., 1993, 32, 343-346.
338. Rangnekar, V.M.; Lokhande, S.R.; Bhamaria, R.P.; Khadse, B.G. Synthesis of N-aryl/substituted-methyl/heteroaryl pyrrolidino/piperidinosuccinimides as antituberculosis agents. Ind. J. Chem., 1983, 22B, 1070-1071.
339. Dave, M.P.; Patel, J.M.; Langalia, N.A.; Shah, S.R.; Thaker, K.A. Studies on the synthesis and antitubercular activity of some aceto-N,N'- diarylsuccinamide. J. Ind. Chem. Soc., 1985, 62(5), 386-387. (Pubitemid 16170736)
340. Okachi, R.; Nijno, H.; Kitaura, K.; Mineura, K.; Nakamizo, Y.; Murayama, Y.; Ono, T.; Nakamizo, A. Synthesis and antibacterial activity of 2,2'-dithiobis(benzamide) derivatives against Mycobacterium species. J. Med. Chem., 1985, 28, 1772-1779. (Pubitemid 16176830)
341. Dabak K, Sezer O, Akar A, Anac O. Synthesis and investigation of tuberculosis inhibition activities of some 1,2,3-triazole derivatives. Eur. J. Med. Chem., 2003, 38, 215-218. (Pubitemid 36288475)
342. Patel, P.; Korgaokar, S.; Parikh, K.; Parekh, H. Synthesis and biological activity of 2-azetidinones, sulphonamides, arylamides and thiourea derivatives. Ind. J. Chem., 1999, 38B, 696-700.
343. Parikh, K.A.; Oza, P.S.; Bhatt, S.B.; Parikh, A.R. Synthesis of some new 2-azetidinones as potential antitubercular agents. Ind. J. Chem., 2000, 39B, 716-718. (Pubitemid 32127056)
344. Ubiali, D.; Pagani, G.; Pregnolato, M.; Piersimoni, C.; Pedraz Muñoz, J.L.; Rodríguez Gascón, A.; Terreni, M. New N-alkyl-1, 2-dihydro-2-thioxo-3-pyridine carbothioamides as antituberculous agents with improved pharmacokinetics. Bioorg. Med. Chem., 2002, 12, 2541-2544. (Pubitemid 35245276)
345. Klimesova, V.; Svoboda, M.; Waisser, K.; Kaustova, J.; Buchta, V.; Kralova, K. Synthesis of 2-benzylthiopyridine-4-carbothioamide derivatives and their antimycobacterial, antifungal and photosynthesis-inhibiting activity. Eur. J. Med. Chem., 1999, 34, 433-440.
346. Shah, H.P.; Shah, B.R.; Bhatt, J.J.; Desai, N.C.; Trivedi, P.B.; Undavia, N.K. Synthesis of 2,5-disubstituted 1,3,4-oxadiazoles as potential antimicrobial, anticancer and anti-HIV agents. Ind. J. Chem., 1998, 37B, 180-182. (Pubitemid 128485842)
347. Mallur, S.G.; Badami, B.V. Novel triheterocyclic systems by Mannich reaction on 3-arylsydnones: Synthesis of 3-aryl-4-[2'-(8"-hydroxy-7"- quinolinylmethylamino)-thiazol-4'-yl]sydnones and 3-aryl-4-[2'-(3"-acetyl- 2"-hydroxybenzylamino)-thiazol-4'-yl]sydnones as possible antimicrobial agents. Ind. J. Chem.; 2001, 40B, 742-747. (Pubitemid 32808165)
348. Udupi, R.H.; Kushnoor, A.S.; Bhat, A.R. Synthesis and biological evaluation of certain pyrazoline derivatives of naproxen. Ind. J. Het. Chem., 1998, 8, 63-66. (Pubitemid 128540664)
349. Nimavat, K.S.; Popat, K.H.; Joshi, H.S. Synthesis, anticancer, antitubercular and amtimicrobial activity of some new pyrimidine derivatives. Ind. J. Het. Chem., 2003, 12, 225-228.
350. Francisco, G.D.; Li, Z.; Albright, J.D.; Eudy, N.H.; Katz, A.H.; Petersen, P.J.; Labthavikul, P.; Singh, G.; Yang, Y.; Rasmussen, B.A.; Lin, Y.I.; Mansour, T.S. Phenyl thiazolyl urea and carbamate derivatives as new inhibitors of bacterial cell-wall biosynthesis. Bioorg. Med. Chem. Lett., 2004, 14, 235-238. (Pubitemid 38016214)
351. Szymanska, E.; Kiec-Kononowicz, K. Antimycobacterial activity of 5-arylidene derivatives of hydantoin. Farmaco, 2002, 57, 355-362. (Pubitemid 34460500)
352. Kabir, M.S.; Namjoshi, O.A.; Verma, R.; Polanowski, R.; Krueger, S.M.; Sherman, D.; Rott, M.A.; Schwan, W.R.; Monte, A.; Cook, J.M. A new classof potential anti-tuberculosis agents: Synthesis and preliminary evaluation of novel acrylic acid ethyl ester derivatives. Bioorg. Med. Chem., 2010, 18, 4178-4186.
353. Karthikeyan, S.V.; Bala, B.D.; Raja, V.P.A.; Perumal, S.; Yogeeswari, P.; Sriram, D. A highly atom economic, chemo-, regio-and stereoselective synthesis and evaluation of spiro-pyrrolothiazoles as antitubercular agents. Bioorg. Med. Chem. Lett., 2010, 20(1), 350-353.
354. Manna, K.; Agrawal, Y.K. Design, synthesis, and antitubercular evaluation of novel series of 3-benzofuran-5-aryl-1-pyrazolyl-pyridylmethanone and 3-benzofuran-5-aryl-1-pyrazolylcarbonyl-4-oxo-naphthyridin analogs. Eur. J. Med. Chem., 2010, 45, 3831-3839.
355. Alemparte G.C.; Barros A.D.; Cacho I.M.; Fiandor R.J.M.; Lavandera D.J.L.; Remuinan B.M.J. Naphthyridin-2 (1 H)-One Compound Useful as Antibacterials, PCT Int. Appl. WO2010081874, July, 2010.
356. Rao, G.K.; Rajasekaran, S.; Pai, P.N.S. Synthesis of some N-(4-oxo-2-substituted-phenylquinazolin-3-(4H)-yl)-2-[(5-aryl-1,3, 4-oxadiazol-2-yl)sulfanyl]acetamides as antitub -ercular agents. Ind. J. Het. Chem., 2010, 19(3), 293-294.
357. Giordano, I.; Hennessy, A.J. Tricyclic Nitrogen Compounds used as Antibacterials, PCT Int. Appl. WO2010043714, April, 2010.
358. Melnic, S.; Prodius, D.; Stoeckli-Evans, H.; Shova, S.; Turta, C. Synthesis and anti-tuberculosis activity of new hetero(Mn, Co, Ni)trinuclear iron(III) furoates. Eur. J. Med. Chem., 2010, 45(4), 1465-1469.
359. Abdel-Aal, W.S.; Hassan, H.Y.; Aboul-Fadl, T.; Youssef, A.F. Pharmacophoric model building for antitubercular activity of the individual Schiff bases of small combinatorial library. Eur. J. Med. Chem., 2010, 45(3), 1098-1106.
360. Hans, R.H.; Guantai, E.M.; Lategan, C.; Smith, P.J.; Wan, B.; Franzblau, S.G.; Gut, J.; Rosenthal, P.J.; Chibale, K. Synthesis, antimalarial and antitubercular activity of acetylenic chalcones. Bioorg. Med. Chem. Lett., 2010, 20(3), 942-944.
361. Pavan, F.R.; Von, P.G.; do Nascimento, F.B.; Leite, S.R.; Batista, A.A.; Deflon, V.M.; Sato, D.N.; Franzblau, S.G.; Leite, C.Q. Ruthenium(II) phosphine/picolinate complexes as antimycobacterial agents. Eur. J. Med. Chem., 2010, 45(2), 598-601.
362. Saikia, D.; Parihar, S.; Chanda, D.; Ojha, S.; Kumar, J.K.; Chanotiya, C.S.; Shanker, K.; Negi, A.S. Antitubercular potential of some semisynthetic analogues of phytol. Bioorg. Med. Chem. Lett., 2010, 20(2), 508-512.
363. Kumar, R.S.; Rajesh, S.M.; Perumal, S.; Banerjee, D.; Yogeeswari, P.; Sriram, D. Novel three-component domino reactions of ketones, isatin and amino acids: Synthesis and discovery of antimycobacterial activity of highly functionalised novel dispiropyrrolidines. Eur. J. Med. Chem., 2010, 45(1), 411-422.
364. Alagarsamy, V.; Venkateshperumal, R.; Sathyabhama, S. Synthesis, antitubercular, antibacterial and antifungal activities of some hydrazones and their spirothiazolidinones. Ind. J. Het. Chem., 2002, 11(4), 327-328. (Pubitemid 40768208)
365. Zhoua, B.; Hea, Y.; Zhang, X.; Xu J, Luo, Y.; Wang, Y.; Franzblau, S.G.; Yang, Z.; Chan, R.J.; Liu, Y.; Zheng, J.; Zhang, Z.Y. Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents. Proc. Natl. Acad. Sci. U S A, 2010, 107, 4573-4578.
366. Lin, G.; Li, D.; Carvalho, P.; Deng, H.; Tao, H.; Vogt, G.; Wu, K.; Schneider, J.; Chidawanyika, T.; Warren, J.D.; Li, H.; Nathan, C. Inhibitors selective for mycobacterial versus human proteasomes. Nature, 2009, 461, 621-626.
367. Barker, J.J. Antibacterial drug discovery and structure-based design. Drug Discov. Today, 2006, 11, 391-404 and references cited therein.
368. Kantardjieff, K.; Rupp, B. Structural Bioinformatic Approaches to the Discovery of New Antimycobacterial Drugs. Current Pharma. Des., 2004, 10, 1-17.
369. Smith, R.M.; Wu, G.Y. Structure-based design of hepatitis C virus inhibitors. J. Viral Hepat., 2003, 10, 405-412. (Pubitemid 37352580)
370. Wlodawer, A. Structure-based design of AIDS drugs and the development of resistance. Vox Sang., 2002, 83, 23-26.
371. Sanchez, R.; Sali, A. Comparative protein structure modeling. Introduction and practical examples with modeller Methods. Mol Biol., 2000, 143, 97-129.
372. Brooijmans, N.; Kuntz, I.D. Molecular recognition and docking algorithms. Annu Rev Biophys Biomol Struct.; 2003, 32, 335-373. (Pubitemid 37056233)
373. Chen, Y.Z.; Zhi, D.G. Ligand-protein inverse docking and its use in the computer search of protein targets of a small molecule. Proteins, 2001, 43, 217-226.
374. Fernandez-Recio, J.; Totrov, M.; Abagyan, R. ICM-DISCO docking by global energy optimizaton with fully flexible side-chains. Proteins, 2003, 52, 113-117. (Pubitemid 36648859)
375. Stevens, D.L. Dotter, B.; Madaras-Kelly, K. A review of linezolid: The first oxazolidinone antibiotic. Expert Rev. Anti. Infect. Ther. 2004, 2, 51-59. (Pubitemid 38735747)
376. Reck, F.; Zhou, F.; Girardot, M.; Kern, G.; Eyermann, C.J.; Hales, N.J.; Ramsay, R.R.; Gravestock, M.B. Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J. Med. Chem., 2005, 48, 499-506. (Pubitemid 40139792)
377. Hwang, J.H.; Kim, J.M.; Kim, Y.T.; Choi, J.D.; Yoon, M.Y. Lag Time of the Recombinant Acetohydroxy Acid Synthase from Tobacco. Bull. Korean Chem. Soc., 2003, 24, 1856-1858.
378. Kim, J.M.; Kim, J.R.; Kim, Y.T.; Choi, J.D.; Yoon, M.Y. Bull. Korean Chem. Soc., 2004, 25, 721-725.
379. Le, D.T.; Choi, J.D. FAD-independent and Herbicide-resistant Mutants of Tobacco Acetohydroxy Acid Synthase. Bull. Korean Chem. Soc., 2005, 26, 1-6.
380. Karim, M.; Shim, M.Y.; Kim, J.M.; Choi, K.J.; Kim, J.R.; Choi, J.D.; Yoon, M.Y. The Catalytic Role of the W573 in the Mobile Loop of Recombinant Acetohydroxyacid Synthase from Tobacco. Bull. Korean Chem. Soc. 2006, 27, 549-555. (Pubitemid 43726761)
381. Zohar, Y.; Einav, M.; Chipman, D.M.; Barak, Z. Acetohydroxyacid synthase from Mycobacterium avium and its inhibition by sulfonylureas and imidazolinones. Biochim. Biophys. Acta., 2003, 1649, 97.
382. Le, D.T.; Lee, H.S.; Chung, Y.J.; Yoon, M.Y.; Choi, J.D. Virtual Screening of Tubercular Acetohydroxy Acid Synthase Inhibitors through Analysis of Structural Models. Bull. Korean Chem. Soc., 2007, 28, 947-952.
383. Adams, M.; Wube, A.A.; Bucar, F.; Bauer, R.; Kunert, O.; Haslinger, E. Quinoline alkaloids from Evodia rutaecarpa: Apotent new group of antimycobacterial compounds. Int. J. Antimicrob. Agents, 2005, 26, 262-264. (Pubitemid 41219616)
384. Lefevre, P.; Peirs, P.; Braibant, M.; Fauville-Dufaux, M.; Vanhoof, R.; Huygen, K.; Wang, X.M.; Pogell, B.; Wang, Y.; Fischer, P.; Metz, P.; Content, J. Antimycobacterial activity of synthetic pamamycins. J. Antimicrob. Chemother., 2004, 54, 824-827. (Pubitemid 39386739)
385. Huang, X.; Roemer, E.; Sattler, I.; Moellmann, U.; Christner, A.; Grabley, S. Lydiamycins A-D: Cyclodepsipetides with antimycobacterial properties. Angew. Chem., Int. Ed. 2006, 45, 3067-3072. (Pubitemid 44099018)